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1. INTRODUCTION 
Investigations of the polymorphism of APIs are currently essential in pharmaceutical research 
and production. This process is known as "polymorph screening". The polymorph screening 
of organic materials is an extremely complex and multifaceted field, which poses considerable 
challenges for innovators and generic companies from the aspects of both pharmaceutical and 
intellectual property rights. 
Polymorphism is a common phenomenon among APIs. Some literature sources suggest that it 
occurs in 32-51% of solid materials [1], whereas other surveys indicate that ~ 90% of 
crystalline active ingredients have polymorphs [2]. The physico-chemical properties of 
polymorph modifications such as melting point, hardness, solubility, dissolution rate, etc. can 
differ as a consequence of the different crystal structures and this may influence the 
formulation, the storage, the absorption, the toxicity, the efficiency and finally the 
bioavailability of the API. The importance of polymorph screening is outstanding since the 
drug registration authorities require a precise description of the characteristics of a solid-state 
API and a drug candidate can be placed on the market only in the case of a specific 
polymorph for which long and expensive biological, toxicological and clinical studies have 
been carried out [3-5]. The intended use of a different polymorph of the same API demands 
the repetition of these studies, which involves a loss of time and money. The 
recommendations of the ICH, prompted by the requirements of the authorities, regulate the 
authorisation of original and generic products, this being accepted by the FDA and the EMA. 
In the synthetic process, most APIs and their salts are purified and isolated by crystallization 
from an appropriate solvent [6]. Many factors can influence crystal nucleation and growth 
during this process, including the composition of the crystallization medium (solvent, solvent 
combinations, additive type, etc.) and the process(es) used [7-9]. Since pharmaceutical 
compounds often have a great number of solid phases, even in a metastable state, their 
interpretation is difficult because of kinetic factors. Various techniques are therefore used for 
the study of polymorphism [10].  
Pharmaceutical dosage forms contain both active ingredients and excipients. Although 
excipients must be inert, they may influence the absorption and bioavailability of the drug in 
such a way as to increase the stability of the formulation, to faciliate the liberation of the API, 
etc. [11]. Additives and impurities can influence the kinetic stability of a polymorph in a 
solution or a suspension by affecting both the nucleation and the growth rate [12, 13]. Their 
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presence may promote the formation of a metastable polymorph, which may otherwise rapidly 
transform to a more stable polymorph [12, 14]. Polymorph screening that is performed with 
additives may therefore lead to different results from a screening performed with a pure batch 
[13]. Among the additives currently utilized in the pharmaceutical industry are the SEs, which 
have likewise long been preferred in the food and cosmetic industries too. They can be 
applied as emulsifiers, solubility and dissolution rate enhancers, gel-formers and crystal 
growth enhancers or inhibitors [15-21]. Szűts et al. reported that a certain type of SE 
influenced the degree of crystallinity of a model drug [22]. Accordingly, since SEs can affect 
the crystal structure of the API, it is useful to investigate the structural changes during 
crystallization processes when SEs are used as additives. 
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2. AIMS 
Polymorph screening is a very complex process during preformulation research. It is not 
sufficient to investigate merely the effects of the organic solvents and the temperature. The 
presence of the different additives, such as the SEs, must also be considered. These 
surfactants may cause changes in the polymorphic form during crystallization, and these may 
finally affect the bioavailability of the drug. 
The aim of my PhD work was therefore to develop a polymorph screening method on a model 
drug and to investigate the influence of different SEs during the crystallization process. 
A.  The main aim of my investigations was to develop a polymorph screening method on a 
failed drug candidate. Different crystallization and transformation methods were used to 
generate the polymorphs of the model drug. Eight polymorphs were obtained and were 
characterized by light microscopy, SEM, XRPD, DSC and Raman spectroscopy. A special 
dissolution test was developed with which the eight polymorphs could be well 
distinguished. 
B. After the characterization of the different polymorphs, their relative stabilities were 
investigated by means of a slurry conversion method, VH-XRPD, VT-XRPD and DSC. 
C. Finally, different types of SEs (widely used as additives at present) were studied during 
the crystallization of the polymorphs in order to establish their polymorph-changing 
effects. 
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3. LITERATURE SURVEY 
3.1. Polymorphism 
The idea of polymorphism was introduced by Mitscherlich at the beginning of the 19th
 
century during his investigations of arsenates and phosphates [23]. Polymorphism is the 
ability of a compound in the solid state to exist in different crystalline forms with the same 
chemical composition. The phenomenon of a molecule existing in more than one solid-state 
structure is a result of differences in packing arrangement and/or molecular conformation [8]. 
ICH Q6A defines polymorphism as “some new drug substances exist in different crystalline 
forms which differ in their physical properties. Polymorphism may also include solvation or 
hydration products (also known as solvatomorphism) and amorphous forms” [24]. 
The polymorphism of a chemical element is known as allotropism. As a simple example, 
diamond and graphite are two allotropes of carbon. Another example is that of phosphorous 
(P4) in cubic (white), monoclinic (purple) and orthorhombic (black) forms [25]. 
Mention should also be of an interesting phenomen related to polymorphism: "disappearing 
polymorphism" [26-28]. This refers to a situation where a previously prepared form no longer 
appears after a more stable form is obtained [29]. The numerous examples of disappearing 
polymorphism include benzylidene-dl-piperitone, benzocaine picrate, mannose, etc. [26]. 
3.2. Thermodynamic relations in polymorphs 
In terms of thermodynamic relations, polymorphic modifications may be monotropes or 
enantiotropes [1], depending on their stability with respect to temperature and pressure. If one 
of the polymorphs is stable (i.e. it has a lower free energy content and solubility) over certain 
ranges of temperature and pressure, while the other polymorph is stable over different ranges 
of temperature and pressure, the two polymorphs are said to be enantiotropes. On the other 
hand, it may occur that only one polymorph is stable at all temperatures below the melting 
point, all the other polymorphs being unstable. Such polymorphs are said to be monotropes 
(Fig. 1). 
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Fig. 1 Variation of energy with temperature for enantiotropic and monotropic systems. Curves 
HA, HB and HL relate to enthalpy, ΔHf,A and ΔHf,B to enthalpy of fusion, and GA, GB and 
GL to free energy. Tt is the transition temperature, M.P. is the melting point and ΔHt is the 
enthalpy of transformation [25] 
In an enantiotropic system, a reversible transition is observed at a definite transition 
temperature at which the free energy curves intersect before the melting point is reached. By 
contrast, for a monotropic system, the free energy curves do not intersect, and therefore no 
reversible transition is observed below the melting point. The polymorph that demonstrates 
the higher free energy curve and higher solubility is called an unstable polymorph. It is 
generally possible to distinguish monotropes and enantiotropes through their heats of fusion. 
Endothermic polymorphic transitions indicate that enantiotropes are involved, whereas 
exothermic ones point to monotropes [25]. 
3.3. The importance of polymorphism in pharmaceutics 
The different polymorphs exhibit different physical and physico-chemical properties, such as 
habit, colour, density, melting point, solubility, dissolution rate, etc. [30]. One reason for the 
importance of polymorphism is that these differences may affect the pharmaceutical 
processing, the bioavailability, the toxicity and the stability of the drug product, and hence the 
therapeutic efficacy of the API [31]. Another aspect is the possibility of a patent. Two of the 
requirements for a patent are novelty and non-obviousness. By definition, a new crystal form 
is novel. Since crystal forms cannot be predicted a priori, they are not obvious. Many new 
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crystal forms are therefore patentable and have been patented [32]. As most APIs in the 
pharmaceutical field are formulated and marketed in crystalline form, this explains the 
importance of this topic. 
3.4. Solid form screening 
Solid form screening is a standard procedure in drug development, but it was not until the late 
20th century that the pharmaceutical industry overall became aware of polymorphism, even 
though the phenomenon had been known since the early 19th century [33]. It was not until a 
number of production problems appeared, such as the sudden occurrence of another form of 
ritonavir (with low solubility and bioavailability) [34], that the industry started to take 
polymorphism seriously. How extensive polymorph screening should be during the early 
development process is well illustrated by McCrone, who in 1965 wrote as follows: "It is at 
least this author’s opinion that every compound has different polymorphic forms, and that, in 
general, the number of forms known for that compound is proportional to the time and money 
spent in research on that compound” [35]. The aim of solid form screening is to find the 
optimum polymorph with the best characteristics (including the physico-chemical, 
pharmaceutical and biopharmaceutical properties) for development. In general, the most 
stable form is preferred over other forms because of its lower tendency to solid phase 
transformations [36]. However, metastable forms are sometimes deliberately chosen, usually 
for better solubility and therefore bioavailability [37]. Solid form screening can be carried out 
both experimentally and computationally. Experimental screening consists in the preparation 
step, during which various forms are generated and isolated, and the analysis step, which 
involves the use of various measurement techniques and analysis of the data. Computational 
methods of polymorph prediction have evolved markedly during recent years, though they 
cannot be fully relied on yet. 
HTS has been integrated into the pharmaceutical discovery process. It utilizes fully automated 
robotic systems capable of performing thousands of crystallizations per week with the 
consumption of only a few grams of API [38, 39]. It is most commonly carried out in 96-well 
plate systems in which the particular solid (~ 0.5-10 mg/sample), dissolved in a suitable 
solvent, is initially dispensed by using automated liquid handling systems. Different levels of 
supersaturation can be achieved, for example by heating/cooling and evaporation, and by 
varying the nominal concentration of the API. During a polymorph screening process, the 
interplay between kinetic and thermodynamic factors must be extensively utilized to discover 
all the relevant solid forms of a compound in question [36]. 
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Thus, the key experimental technique used to perform solid form screens is crystallization. 
The methods applied to generate polymorphs are summarized in Table 1. The techniques that 
I used are discussed in detail. 
Table 1 Methods of generating polymorphs [29] 
Crystallization from a single or mixed solvents/HTS [40-44] 
Thermal activation of solid substrates [45] 
Crystallization from the melt [46-48] 
Desolvation/dehydration of solvates/hydrates by heat or by reslurrying [49, 50] 
Crystallization in nano-confined structures [51-53] 
Seeding/pseudoseeding [54, 55] 
Solution-mediated polymorphic transformation/slurry conversion methods [56-59] 
Solid-state polymorphic transformation [49, 60] 
Mechanical activation of a solid substance [61, 62] 
Crystallization in a capillary tube [63, 64] 
Exposure to vapour at high or low humidity [65-67] 
Exposure to organic vapour [68] 
Direct crystallization on molecular substrates [69-74] 
Crystallization in the presence of tailor-made additives [75-89] 
Laser-induced crystallization [90, 91] 
Crystallization from a supercritical fluid [92-94] 
Structure prediction in silico [95-99] 
 
Crystallization from single or mixed solvents 
Polymorph screening is generally carried out by crystallization from single or mixed solvents, 
through cooling or evaporation of the solvent or addition of an antisolvent to the solution 
[100]. It is a great challenge to select appropriate solvents for solid screening: it is necessary 
to consider physicochemical properties such as the hydrogen-bond acceptor/donor propensity, 
polarity/dipolarity, dipole moment, dielectric constant, miscibility, etc. [101]. Classically, the 
crystallization process is described in terms of two distinct steps, nucleation and crystal 
growth [102], with the resulting physical form being a consequence of the kinetic relationship 
between these two elementary processes. Many factors (e.g. heating and cooling rates, 
temperature, evaporation rate, degree of supersaturation, pH or pH change of the medium, 
etc.) can influence the crystallization process, and polymorphs are therefore formed [29]. 
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Thermal transformation 
As concerns the thermodynamic relationship between polymorphs, it was stated in section 3.2 
that any given two polymorphs can be either monotropic or enantiotropic [29]. In an 
enantiotropic system, the form that is metastable at room temperature can be obtained by 
heating the form that is stable above the transition temperature. In a monotropic system, the 
stable form at room temperature can be obtained by heating the metastable form at any 
temperature. The rate of transformation can be facilitated by heating the metastable form at 
high temperature. By starting with the stable form, it is impossible to obtain the metastable 
form by thermal activation in a monotropic system. The transition temperature can be 
estimated by observing the transition events during DSC measurements [103], by slurrying 
mixtures of polymorphs over certain temperatures [104, 105] or by calculating the Gibbs free 
energy differences between polymorphs over temperature ranges via direct heat capacity 
measurements [106]. 
Desolvation/dehydration of solvates/hydrates by heating or by reslurrying 
On increase of the number of experiments during the screening process through extension of 
the HTS and polymorphic screening methods, the number of hydrates/solvates discovered 
during the screening process may increase [107]. When dehydration or desolvation occurs, 
such solvates/hydrates can undergo phase transitions which may result in non-
solvated/anhydrous polymorphs [108, 109] or in the loss of crystallinity and the formation of 
amorphous products [110]. Isomorphic desolvates/dehydrates can sometimes be formed, 
which means that solvent/water molecules leave the crystals without affecting the crystal 
structures of the solvates/hydrates [111, 112]. Desolvation/dehydration processes are usually 
conducted at low relative humidity or low organic vapour pressure. It has recently been 
demonstrated that desolvation with the use of the reslurrying of solvates in a solvent with poor 
solubility at low or high temperature can yield pharmaceutically relevant polymorphs [113]. 
3.5. Additive-induced polymorph selection 
Additive-induced polymorphism has always interested solid-state chemists for fundamental 
and practical reasons [114]. Additives can inhibit nucleation by being incorporated into the 
prenuclear aggregates/crystals or by binding to the nuclei/crystals. There are three 
possibilities for the inhibition of nucleation/crystal growth by means of additives: 
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As the possibility additives prevent prenuclear aggregates of a particular form from growing 
into a nucleus with a critical radius by creating defects in the aggregates [115]. As a result, the 
prenuclei redissolve into the solution. In this respect, additives can decrease the rate of 
nucleation by increasing the critical supersaturation for nucleation and/or interfacial tension. 
Alternatively, additives can favourably attach to the prenuclei of a certain form of a 
polymorph or enantiomer [116], other polymorphs remaining unaffected by the additives. As 
a consequence, the unaffected prenuclei grow into the nuclei with a critical radius size, and 
become the resultant crystals. 
The third possibility is for additives to attach to the fastest-growing face of the stable 
polymorph, which prevents the stable form from growing [117]. As a result, the metastable 
polymorph crystallizes [29]. Inhibition of the growth of a specific face will result in changes 
in morphology, dissolution rate and/or polymorph selection [118]. Different sucrose 
oligoesters added to palm kernel oil have been described as crystallization-accelerator 
additives [119]. 
3.6. The importance of sucrose esters in pharmaceutics 
SEs are widely used in the food and cosmetics industries, and there has recently been great 
interest in their applicability in different pharmaceutical fields [120]. They are biodegradable, 
natural, non-ionic surface-active agents consisting of sucrose as hydrophilic moiety and fatty 
acids as lipophilic groups (Fig. 2). SEs can be characterized by their HLB values. Thanks to 
the wide range of these values (1-16), the SEs can be applied in many fields of pharmaceutical 
technology, such as the release or the absorption of modifying agents, o/w or w/o emulsifiers, 
wetting and solubilizing agents or lubricants [121-130].  
 
 
Fig. 2 General chemical structure of SEs 
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Table 2 Examples of the different types of SEs 
Type Fatty acid HLB 
B 370 Behenic acid 3 
S 370 Stearic acid 3 
S 1570 Stearic acid 15  
O 1570 Oleic acid 15 
P 1670  Palmitic acid 16 
M 1695 Myristic acid 16  
L 595 
L 1695  
Lauric acid 
Lauric acid 
5 
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3.7. Methods of investigation polymorphism and solvatomorphism 
Characterization by different microscopic methods 
A complement of physical characterization methods have been developed for the study of 
polymorphs and solvates, including microscopy, crystallography and thermal analysis.  
Optical crystallography, which includes light microscopy, is directly applicable to organic 
chemicals. This technique is based on the fact that light travels at different speeds in different 
directions in a crystal [131]. During the examination of crystals by microscopy, their 3D 
shapes can be characterized simply and quickly. Light microscopy can also be used to 
estimate the particle size distribution in a powder sample. A quicker and more efficient 
method is to use a computer-controlled image analyser with a motorized specimen stage and a 
camera [1]. Another combination of traditional microscopy with a hot-stage accessory is 
HSM. During pharmaceutical development, HSM is a preferred choice that is mostly used to 
support DSC results, because it provides visual and semiquantitative information concerning 
the transition of pharmaceutical polymorphs [132]. It provides a unique insight into 
polymorphic transitions and the thermal behaviour exhibited by different crystal forms of a 
compound [133, 134]. SEM has many advantages over traditional microscopy. It is used to 
observe the surfaces of materials at high resolution [135]. Depending on the instrument used, 
specimens can be magnified roughly between 10 and 100,000 times, thereby allowing the 
detection of much greater detail than with light microscopy [136, 137]. EDS is a powerful 
technique that is ideal for revealing what elements are present in a particular specimen. The 
initial EDS analysis usually involves the generation of an X-ray spectrum from the entire area 
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scanned by SEM. Through the process of X-ray mapping, information about the elemental 
composition of a sample can then be overlaid on the magnified image of the sample [138]. 
Different spectroscopic methods 
During polymorphism screening, additional valuable information can be obtained by 
vibrational spectroscopy methods such as Raman and IR spectroscopy, which are most 
widely used since they are easy to handle and involve relatively low cost. Conventional IR 
spectrometers have a low energy cut-off around 200-400 cm
-1
, while Raman scattering is the 
only method with which the complete vibrational spectrum of a molecule  (from 4 to 
4000 cm
-1
) can be easily recorded. Raman spectroscopy generally has better spectral 
selectivity (for the distinction of polymorphic forms including the amorphous state) as the 
symmetric stretching linked to the carbon skeleton is more expressed than in IR spectroscopy, 
and in contrast with IR spectroscopy, it is not disturbed by the presence of water. The main 
advantages of Raman and IR spectroscopy include the fast and non-invasive measurements, 
the in situ and on-line monitoring capabilities, the lack of sample preparation, quantitative 
analyses, etc. [32, 139, 140]. 
SsNMR spectroscopy with cross-polarization and magic-angle spinning is a powerful 
crystallographic method for the investigation of crystalline polymorphs and the relative 
crystalline and amorphous contents of pharmaceutical excipients. It can also be used to 
identify the number of crystallographically non-equivalent sites, since each 
crystallographically unique molecule in the unit cell gives rise to an NMR signal [141]. 
X-ray methods 
XRPD is the front-line technique for the analysis of polymorphs. It can be used (like IR 
spectroscopy) for the quantitative analysis of polymorph mixtures, and as an analytical tool 
for high-throughput screening with some modifications. However, when the reference powder 
patterns of pure forms are not available, it is often difficult to ascertain whether a powder 
pattern is from the mixture or pure material. In that case, single-crystal X-ray analysis is 
necessary [29]. XRPD is commonly used to investigate the structures of variable hydrates, 
which are crystalline species that contain non-stoichiometric amounts of water held within 
channels in the crystal lattice. VH-XRPD studies with XRPD instruments equipped with a 
variable-humidity sample stage allow in situ analyses of samples externally conditioned under 
various relative humidity environments [142]. By means of VT-XRPD, a technique in which 
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XRPD experiments are carried out at different temperatures [143], complex pharmaceutical 
solid-state reactions, including crystal structure transformations, can be characterized in situ 
[144, 145]. The VT and VH sample chambers of the XRPD instrument allow the crystal form 
changes associated with the changing conditions to be followed [146]. Single-crystal X-ray 
analysis is a non-destructive technique which provides information on the internal lattices of 
crystalline substances, and also unit cell parameters such as bond lengths, bond angles and 
unit cell types [147]. However, it is often very difficult to obtain a crystal suitable for single-
crystal X-ray analysis, and especially metastable forms. 
Thermal analysis 
Other important methods that are widely used in the pharmaceutical industry for the 
characterization of polymorphism, solvation and purity are the various forms of thermal 
analysis, which include TG, DTG and DSC. Crystalline states or forms exhibit different 
levels of thermodynamic stability and an unstable form can melt at a temperature significantly 
lower than the melting point of the thermodynamically stable form. The different polymorphic 
forms can therefore be identified through their melting profiles and melting points, which can 
be detected by calorimetric methods. The samples are subjected to increasing temperature in 
order to detect peaks reflecting the loss of matter (DTG), or the release of energy in the form 
of heat (DSC). DSC measures heat flow into or from a sample during heating or cooling or 
under isothermal conditions. For the characterization of solvates and hydrates, the use of both 
DSC and TG is needed [148]. Although these two techniques are quite sensitive, they are not 
specific: the solid transformations may have too low energies, impurities have a high impact 
on the melting points and the amorphous content influences the measured melting enthalpies 
[10, 149]. DSC data can be also used to determine the relative stability of polymorphs [150]. 
Combined techniques can be extremely helpful for both the characterization and the 
determination of the sequence of stability of polymorphs. TG-IR or TG-MS is used if the 
identity of the volatile component is determined in situ [10]. HSM combines the best 
properties of microscopy and thermal analysis to permit the solid-state characterization of 
materials as a function of temperature [151]. VT-XRPD provides the required information to 
ascertain whether an evolved gas is due to solvent incorporated in the crystal lattice or 
physically adsorbed on the solid [152]. 
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Other methods 
For thermodynamic reasons, a drug exhibiting crystal polymorphism should display different 
thermodynamic activities, depending upon its crystalline modification. The rate of the release 
of the drug from any solid dosage form, in vivo or in vitro, may be strongly dependent on this 
when the rate process is controlled by diffusion. Since solubility or drug dissolution is related 
to drug absorption, it is also very important to perform dissolution studies. During the initial 
stages of the development of a pharmaceutical, the polymorphic form should be selected that 
best meets the two most important requirements of stability and solubility [153]. The 
solubility of a crystal in a solvent is a reflection of how stable the crystal is. The crystalline 
structure/polymorphic form with the highest stability always has the lowest solubility. The 
more stable it is, the lower its tendency to dissolve in the surrounding solvent [154]. 
Methods of relative stability examination  
During pharmaceutical production, materials pass through many processes which may cause 
polymorph transformation, such as compression, granulation, grinding, drying or 
pulverization [143, 155]. Polymorphs have different lattice energies, and forms with higher 
energy tend to transform into forms with lower energy [8]. Storage conditions, such as 
humidity or temperature, affect the stability of crystal forms [156], and clarification of the 
thermodynamic stability relations between the polymorphs is therefore essential during the 
polymorph screening process. The most stable polymorph usually possesses the lowest Gibbs 
free energy [157]. The slurry conversion method is a technique in which an experiment is 
performed with a programmable temperature control hot stage in which the sample is stirred 
in suspension form at different temperatures. After a certain number of hours or days, the 
excess solid is removed for analysis by XRPD [158]. In situ crystal structure transformations 
can readily be followed by VH-XRPD and VT-XRPD [144-146]. Other important methods 
of detecting polymorph transitions are calorimetric methods such as DSC or MTDSC. 
MTDSC differs from conventional DSC in that the sample is subjected to a more complex 
heating program, incorporating a sinusoidal temperature modulation accompanied by an 
underlying linear heating jump ramp. While DSC measures the total heat flow, MTDSC can 
also distinguish reversible (heat capacity component) and non-reversible (kinetic component) 
heat flows [159]. The heating rate may have a great influence on the kinetics and the 
resolution of peaks in DSC curves [154]. At a comparatively high heating rate (e.g. 100 °C 
min
-1
), the kinetics of the melting transition is changed as if there were not enough time for 
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recrystallization of the higher melting form [160]. With fast-scan DSC, the melting of the 
metastable polymorph can be distinguished from any subsequent recrystallization because the 
later event is moved to a higher temperature and provides separation of the events [161]. 
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4. MATERIALS AND METHODS 
4.1. Materials 
My Ph.D. work related to the polymorphism of a failed drug candidate, 3-[2-({[1-(2-
cyclohexylethyl)-5-(2,5-dimethoxy-4-methylphenyl)-1H-1,2,4-triazol-3-yl]amino}carbonyl)-
6-methoxy-4,5-dimethyl-1H-indol-1-yl}propanoic acid (Sanofi Pharmaceutical Company, 
Budapest, Hungary) (Fig. 3). 
 
Fig. 3 Chemical structure of the model drug 
 
In the first step relating to the crystallization of the various polymorphic forms of the model 
drug, I used different organic solvents of analytical grade: acetonitrile, methanol, 96% ethanol, 
abs. ethanol, isopropanol, acetone, 2-butanone, toluene (Merck, Budapest, Hungary), 
dichloromethane, ethyl acetate, butyl acetate, chloroform, 1,4-dioxane (Reanal, Budapest, 
Hungary) and tetrahydrofuran (Aldrich, Budapest, Hungary).  
After crystallization of the model drug in the pure solvents, the same method was repeated in 
the presence of SEs (Mitsubishi-Kagaku Foods Corporation, Japan) with low (S 370 and L 
595) or high HLB values (S 1570, O 1570 and D 1216). 
4.2. Sample preparation 
Preparation of polymorphs by crystallization 
Different techniques were used for the preparation of the polymorphs (Table 3). 
Crystallization by shock cooling: ~100 mg of the raw material was dissolved at the boiling 
point of the solvent to give a saturated solution which was then diluted with a small amount of 
the solvent. The hot solution was filtered by a "Canula 10 μm" filter into a vial immersed into 
crashed ice. 
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Crystallization by slow cooling: The same process of dissolution was used, but the filtered, 
hot solution was cooled down slowly (-3 °C/h). 
Crystallization by slow evaporation: The products were the dried residues of the clear 
filtrates of the samples prepared by shock cooling. 
Preparation of polymorphs by heating transformation 
Two of the former drug candidate's polymorphs (Form II and IVb) could be generated by 
heating processes at various temperatures for different periods of time from the polymorphs 
generated by crystallization. When Form I was heated on 160 °C during 6 hours, it 
transformed to Form II. In case of Form IVb the same process was applied on Form IVa, but 
on higher temperature (205 °C). (At the early beginning of the polymorph screening of this 
former drug candidate, it was not possible to decide if Form IVa and IVb are a mixture of two 
polymorphs or they are pure polymorphs, but the further analytical investigations could prove 
that they are separate forms.) 
Preparation of polymorphs by crystallization in the presence of sucrose esters 
After the differentiation of the polymorphic forms by means of analytical examinations, the 
single-solvent recrystallizations were repeated in the presence of one or other SE. The 
different SEs were chosen on the basis of their HLB values (Table 4). The solubilities of 
these five SEs in the organic solvents used were determined previously during the single-
solvent recrystallizations. During the additive-induced crystallization, the given SE was 
simultaneously dissolved in the given solvent with the model drug in a mass ratio of 1:1. 
Table 3 The techniques used for the preparation of the polymorphs 
Form Method Solvent Circumstances 
I crystallization 96 %, abs. ethanol shock cooling 
II heating - 160 °C/6 h (from Form I) 
III crystallization isopropanol, 2–butanone, 
butylacetate, ethylacetate, 
toluene  
shock cooling 
IVa crystallization methanol shock cooling 
IVb heating - 205 °C/6 h (from Form IVa) 
V crystallization chloroform shock cooling, slow cooling, slow 
evaporation 
VI crystallization acetone, methanol, 
dichlormethane, 1,4–
dioxane  
shock cooling, slow cooling, slow 
evaporation 
VII crystallization acetonitrile shock cooling 
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Table 4 SEs and solvents used during the additive-induced crystallizations 
SE Solvent HLB API:SE mass ratios 
S 370 chloroform, dichloromethane  3 1:1 
S 1570 chloroform 15  1:1 
O 1570* 96%, abs. ethanol, butyl acetate, methanol, chloroform, 
dichloromethane, 2-butanone, isopropanol 
15 1:1, 1:2, 1:4, 2:1, 4:1 
L 595* 
 
 
D 1216  
96%, abs. ethanol, butyl acetate, methanol, chloroform, 
dichloromethane, 2-butanone, isopropanol, ethylacetate, 
toluene, acetone 
96%, abs. ethanol, 2-butanone, isopropanol,  
methanol, chloroform, acetone 
5 
 
 
16 
1:1, 1:2, 1:4, 2:1, 4:1 
 
1:1 
* In the cases of the SEs O 1570 and L 595, which had polymorph-changing effects, and additional ratios were 
also tested. 
4.3. Polymorph investigation methods 
The particle size distribution of the drug candidate was investigated by light microscopy 
using a LEICA Image Processing and Analysis System (LEICA Q500MC, LEICA Cambridge 
Ltd., Cambridge, United Kingdom). The particles were described in terms of their length, 
breadth, surface area, perimeter and roundness which is a shape factor giving a minimum 
value of unity for a circle. This is calculated from the ratio of perimeter squared to area using 
the following formula: 
064.14
2


Area
Perimeter
Roundness

 
The adjustment factor of 1.064 corrects the perimeter for the effect of the corners produced by 
the digitization of the image. 
The morphology of the particles was examined by SEM (Hitachi S4700, Hitachi Scientific 
Ltd., Tokyo, Japan) having a magnification of 1000x. A sputter coating apparatus (Bio-Rad 
SC 502, VG Microtech, Uckfield, United Kingdom) was applied to induce electric 
conductivity on the surface of the samples. The air pressure was 1.3-13.0 mPa.  
Raman spectra were recorded at room temperature by using a Bruker SENTERRA 
Dispersive Raman Microscope (Bruker Optik GmbH, Ettlingen, Germany) equipped with Nd-
YAG (532 nm) and diode (785 nm) excitation lasers and a cooled CCD detector. The system 
was fitted with a motorized XYZ sample stage. The equipment was controlled by OPUS 6.5 
software (Bruker Optik GmbH, Ettlingen, Germany). Samples were analyzed on glass slides. 
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Following a parameter optimization process, the samples were measured by Nd-YAG (532 
nm) laser at a laser power of 10 mW. An integration time of 5 s, and 3 scans were used for 
each measurement, and spectra were collected over the Raman shift range of 3500-60 cm
−1 
at 
a resolution of 3-5 cm
−1. The microscope magnification was 200× and a certain crystal was 
selected for analysis with a 50 μm × 1000 μm grating. Single Raman spectra of the individual 
crystals were collected in each case. 
XRPD spectra were recorded with a BRUKER D8 Advance diffractometer (Bruker AXS 
GmbH, Karlsruhe, Germany) system with Cu Kα1 radiation (λ = 1.5406 Å) over the interval 
2.5-40 °/2θ. The measurement conditions were as follows: target, Cu; filter, Ni; voltage, 40 
kV; current, 40 mA; time constant, 0.1 s; angular step 0.016°. Detector: NaI (Tl) scintillation 
detector. 
DSC curves were obtained by a Mettler Toledo DSC27HP apparatus (Mettler-Toledo AG, 
Greifensee, Switzerland) under the following conditions: sample weight: about 2-3 mg; 
sample holder: aluminum crucible (40 μL) with lid; nitrogen flow rate: 100-150 mL/min; 
heating rate: 10 °C/min from 25 °C up to 250 °C. In every case, samples were held at 25 °C 
for 10 min before recording. 
Dissolution rate was also studied by a modified paddle dissolution apparatus (Pharmatest, 
Hainburg, Germany) at a paddle speed of 100 rpm. 100 mL of dissolution medium was placed 
in a 37 °C (±0.5 °C) bath and the examination was performed for 2 h. Because of the poor 
solubility of the model drug, neither gastric acid nor intestinal fluid could be used alone. 
Therefore, an appropriate dissolution medium had to be developed. The preliminary 
examination of the model compound showed that its solubility depends on pH: at low pH 
(gastric acid) is worse than at neutral pH (intestinal fluid), therefore intestinal fluid (pH = 6.8) 
was chosen, but the dissolution even in intestinal fluid was not up to 100 %. As all the 8 
polymorphs dissolved well in 96 % ethanol, the optimum mixture of 96 % ethanol: intestinal 
fluid (pH = 6.8) was found of a volumetric ratio of 3:7. The concentration of each polymorph 
solution was determined spectrophotometrically at 324 nm (Unicam UV/vis 
spectrophotometer, Unicam Limited, Cambridge, United Kingdom). The dissolution 
experiments were conducted in triplicate and standard deviation was also calculated. 
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4.4 Relative stability examination of the polymorphs 
Slurry conversion method 
An automatic laboratory reactor system (Avantium Crystal 16, Amsterdam, The Netherlands) 
was used to investigate the relative stabilities of the different polymorphs in suspension. 
Crystal 16 is a multiple reactor system working as a parallel crystallizer on a 1 mL volume 
scale, equipped with an online turbidity probe. The organic solvents for the relative stability 
examination were chosen with regard to the solubility properties of each polymorph. The 
different polymorphs were stirring in suspension in 96 % ethanol and in silicone oil. 96 % 
ethanol was regarded as a "moderately good" solvent of the polymorphs and silicone oil as a 
heat-transferring medium, because in some cases the polymorph transformation is achieved at 
high temperature (> 200 °C), therefore it had to be look for an inert, non-volatile liquid. 100 
mg samples of the polymorphs were examined in 1 mL of 96 % ethanol or silicone oil for a 
maximum of 130 days at room temperature, 50 or 70 °C (in the case of ethanol) or at 200 °C 
(in case of silicone oil). Samples of the suspensions were taken out from time to time with a 
glass pipette, filtered and placed on a Si low-background smooth-surfaced sample holder, and 
the crystals obtained were measured by XRPD. 
Variable humidity and temperature X-ray powder diffractometry  
VH/VT-XRPD patterns were recorded with a Bruker D8 Advance diffractometer (Bruker 
AXS GmbH, Karlsruhe, Germany) system with Cu Kα1 radiation (λ = 1.5406 Å) in the 
interval 2.5-40 °/2θ. The diffractometer was equipped with a hot-humidity chamber (MRI 
Physikalische Geräte GmbH, Karlsruhe, Germany) controlled by an Ansyco Sycos H-Hot 
(Analytische Systeme und Componenten GmbH, Karlsruhe, Germany) and a Våntec 1 line 
detector (Bruker AXS GmbH, Karlsruhe, Germany), which indicated the phase transitions of 
the polymorphs directly in the diffractometer chamber. The measurement conditions were as 
follows: target, Cu; filter, Ni; voltage, 40 kV; current, 40 mA; time constant, 0.1 s; angular 
step, 0.007°. The parameters of the VH-XRPD investigations: humidity between 20 and 80 
RH% in 10 RH% increments, and repeated measurement at 20 RH%. The temperature was 
30 °C. The VT XRPD studies were carried out between 30 and 230 °C, in increments of 5 °C. 
After the series of measurements, the samples were cooled back to 30 °C and measurements 
were repeated immediately after cooling and one day later. 
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Differential scanning calorimetry 
The DSC analysis was carried out with a Mettler Toledo STARe thermal analysis system, 
version 9.30 DSC 821e (Mettler-Toledo AG, Greifensee, Switzerland), at a linear heating rate 
of 1, 10 or 30 °C min-1, with nitrogen as carrier gas (100 mL min-1). The sample weight was 
in the range 2-5 mg and examinations were performed in the temperature interval 25-250 °C, 
in a sealed 40 μL aluminium crucible having two leaks in the lid. In every case, samples were 
held at 25 °C for 10 min before measurements. The MTDSC parameters were as follows: 
temperature interval, 25-250 °C; heating rate: 10 °C min-1; amplitude: 0.5 or 1 °C; period: 0.5 
or 1 min. 
21 
 
5. RESULTS 
5.1. Characterization of the polymorphs  
The objectives here were to distinguish the different polymorphic forms by analytical 
methods, to investigate the relative stability of the polymorphs and to determine the results of 
SE-induced polymorph selection. 
Light microscopy 
First, the particle size distribution was analyzed by light microscopy. Most of the particles had 
sizes in the range 10-25 μm. The smallest particles were those of Form IVa, and the largest 
were those of Form VI. Form I and II gave very similar average results. Form V exhibited the 
smallest roundness value which explains the best dissolution profile. Form II and IVb were 
prepared by heating, transforming one polymorph into another, and there was no significant 
difference in particle size (Table 5).  
 
Table 5 The average results of the particle size analysis 
Form 
 Length Width Perimeter Area Roundness 
 [μm] [μm] [μm] [μm]2  
I 
  
Average 22.7 12.7 68.7 214.9 1.99 
SD± 13.7 6.6 45.3 300.5 1.13 
II 
  
Average 22.5 13.1 77.8 203.1 2.41 
SD± 12.5 7.0 69.2 201.6 2.18 
III 
  
Average 20.4 12.2 62.7 231.8 1.77 
SD± 13.8 8.7 46.2 336.7 0.75 
IVa 
  
Average 10.4 4.6 27.6 33.2 1.85 
SD± 4.1 1.7 11.2 21.8 0.61 
IVb 
  
Average 17.8 6.3 44.3 78.6 2.10 
SD± 11.4 3.3 28.5 84.4 1.00 
V 
  
Average 20.3 14.3 61.9 259.9 1.38 
SD± 11.8 8.3 40.2 334.7 0.43 
VI 
  
Average 109.8 63.5 354.2 5348.4 2.12 
SD± 62.2 40.2 279.0 5970.1 1.44 
VII 
  
Average 31.2 20.0 106.3 476.8 2.23 
SD± 17.9 11.5 88.9 541.7 1.97 
Scanning electron microscopy 
The SEM pictures (Fig. 4) reveal that the crystals of the polymorphs present differences in 
size, morphology and surface. Form I (shock cooling in ethanol) resulted in long needle-
shaped crystals. When Form I was heated to 160 °C, the transformation led to a new 
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morphology. Form II contained prismatic crystals in size range of 25-60 μm. Form III 
obtained by shock-cooling in isopropanol, 2-butanon, or ethyl acetate gave mostly irregular 
trapezoid crystals with a smooth surface around 50 μm. Form V crystals obtained by shock 
cooling in chloroform are around 25 μm, with a nearly ditrigonal morphology. The 
morphology of Form IVa obtained by shock cooling in methanol and Form IVb obtained by 
heating of Form IVa were very similar, involving slender ditrigonal and ditetragonal prisms. 
The crystals of Form IVa were smaller than those of Form IVb. The crystals of Form VI and 
Form VII were very irregular and varied in size. 
   
FI       FII 
   
FIII       FIVa 
   
FIVb     FV 
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FVI      FVII 
Fig 4 The SEM pictures of the eight forms 
Raman spectroscopy 
The model drug contains Raman-sensitive C-O-C, C=O, C-N(-N-), methyl and carboxyl 
groups and cyclohexane, triazole, aromatic and indole rings. There are clear differences 
between the Raman spectra of the polymorphs in the ranges 3200-2800 cm
-1
 and in particular 
1800-900 cm
-1
 (Figs 5 and 6). The Raman spectra of Forms I and IVb demonstrate low 
Raman intensities (5000 and 900) relative to the other forms (16,000-40,000). Moreover, 
Form IVb exhibits an unfavourable signal-to-noise ratio and slight fluorescence behaviour. In 
the range 3000-2800 cm
-1
, each of the polymorphs gives a characteristic peak, e.g. at 2843 
cm
-1
. Forms III and VII can readily be distinguished through the weak peaks at 3042, 2966 
and 3010 and 2990 cm
-1
, respectively. 
In the interval 1800-900 cm
-1
, further differences can be observed. All the forms have 
characteristic bands at 1685 (C=O stretching), 1630-1615 (indole ring vibration and 
hydrazone ring stretching), 1550 (1,2,4,5-tetrasubstituted benzene ring stretching), 1511 (-
C=C- stretching), 1405 (aromatic N=N vibration), 1375 and 1358 (1,2,4-triazole N2-C3 and 
N4-C5 stretching), 1208 (aromatic =C-H in-plane deformation), 1050 (cyclohexane C-C 
skeletal vibration) and 926 cm
-1
 (C-O-C vibration), and additionally at 1473, 1358, 1305 and 
1141 cm
-1
 (without assignment). Form V has unique peaks at 1677 (C=O stretching) and 
1036 cm
-1
, while Form VII also has singular peaks at 1694, 1325 and 1247 cm
-1
. 
Muniz-Miranda et al. [162] concluded that the strongest characteristic Raman band of the 
1,2,4-triazole ring depends on the distances between the ring atoms and hence on the aromatic 
ring geometry. No peaks are observed at 1520, 1291, 1259, 1160 and 1068 cm
-1 
in the Raman 
peaks on the Raman spectra (Figs 6). The ring deformation at 1375 cm
-1
 is attributed to the 
N2-C3 and N4-C5 stretching modes of the 1,2,4-triazole ring (Fig. 7). It should be noted that 
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this type of N2-C3/N4-C5 bond stretching is a result of a special type of ring deformation, the 
reason being the substitution on N2, C3 and C5 of the triazole ring.  
 
Fig. 5 Raman spectra of the 8 polymorphs 
 
 
Fig. 6 Raman spectra of the 8 polymorphs 
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Fig. 7 Optimized geometry of the 1,2,4-triazole ring (left) and the estimated ring deformation 
(right) (N2-C3 and N4-C5 stretching) 
X-ray powder diffractometry 
The XRPD patterns of the eight polymorphs are shown in Fig. 8. The characteristic diffraction 
peaks are presented in Table 6. The data in Table 6 indicate that the characteristic peaks are 
situated between 4 and 26° 2θ. All the eight polymorphs (with the exception of Forms IVa 
and IVb) exhibit clear XRPD differences, but these two forms can be well distinguished by 
other methods, though the crystal structure of Form IVa and IVb were very similar. 
 
Fig. 8 The XRPD patterns of the eight polymorphs 
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Table 6 The characteristic diffraction peaks of the eight polymorphs  
 
  
d (Å) 2 θ (°) 
Intensity 
(CPS) 
I/I1 
(%) 
Form 
I 20.054 4.403 10.30 100.0 
  10.388 8.505 0.61 5.9 
  6.640 13.319 0.92 8.9 
  5.926 14.937 0.89 8.7 
  4.995 17.744 1.00 9.7 
  4.156 21.360 6.71 65.0 
  3.398 22.300 2.58 25.0 
  3.463 25.707 1.01 9.8 
  2.605 34.405 0.49 4.7 
  2.429 36.983 0.40 3.9 
Form 
II 18.386 4.802 24.50 100.0 
  8.212 10.756 7.99 32.6 
  6.023 14.696 4.10 16.7 
  5.694 15.549 4.98 20.4 
  5.085 17.428 4.32 17.6 
  4.587 19.336 5.51 22.5 
  4.387 20.225 6.25 25.5 
  4.117 21.570 4.85 19.8 
  3.684 24.139 14.40 58.7 
  3.562 24.977 3.35 13.7 
Form 
III 10.715 8.245 16.30 100.0 
  9.579 9.224 0.71 4.4 
  9.125 9.685 1.56 9.6 
  8.419 10.498 1.59 9.8 
  8.043 10.992 0.78 4.8 
  4.207 21.099 2.09 12.9 
  4.038 21.995 2.49 15.3 
  3.636 24.465 0.98 6.0 
  3.572 24.903 1.47 9.0 
  2.908 30.719 0.66 4.0 
Form 
IVa 12.531 7.048 2.28 34.6 
  10.005 8.831 2.09 31.8 
  8.304 10.645 1.93 29.3 
  6.276 14.100 3.03 46.0 
  5.329 16.622 2.27 34.5 
  4.816 18.408 3.16 48.0 
  4.448 19.947 1.95 29.7 
  4.166 21.309 6.59 100.0 
  3.617 24.592 3.05 46.3 
  3.486 25.533 2.51 38.2 
Form 
IVb 12.543 7.042 72.40 53.1 
  10.041 8.799 94.50 69.3 
  8.286 10.669 81.20 59.6 
  6.304 14.037 81.90 60.1 
  5.342 16.582 82.10 60.3 
  5.186 17.083 78.50 57.6 
  4.444 19.962 72.70 53.4 
  4.175 21.263 136.00 100.0 
  4.120 21.550 72.70 53.4 
  3.627 24.521 62.30 45.7 
Form 
V 19.665 4.490 0.41 5.1 
  16.458 5.365 8.01 100.0 
Form 
VI 10.818 8.167 2.56 32.4 
  8.163 10.830 0.63 8.0 
  5.766 15.355 0.70 8.9 
  5.419 16.343 7.88 100.0 
  4.144 21.423 1.67 21.2 
  3.819 23.267 4.68 59.4 
  3.743 23.750 0.68 8.6 
  3.627 24.595 3.28 41.6 
  3.121 28.582 0.58 7.4 
  2.406 37.350 0.59 7.4 
Form 
VII 17.004 5.193 14.30 100.0 
  10.306 8.573 8.61 60.3 
  9.715 9.096 8.50 59.5 
  8.833 10.006 2.81 19.7 
  6.208 14.255 4.92 34.4 
  5.154 17.191 2.63 18.4 
  4.892 18.121 2.25 15.8 
  4.164 21.321 7.67 53.7 
  3.876 22.925 3.95 27.7 
  3.446 25.835 2.46 17.2 
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Differential scanning calorimetry 
The DSC curves and the relevant data of the eight polymorphs are shown in Table 7 and Fig. 
9. The eight forms give different DSC patterns, except for Form I and II which display a 
single endothermic peak at about 232 °C (under the DSC conditions, Form I is converted to 
Form II). Without melting, the transformation of Form I-II could be observed by hot-stage 
microscopy. Forms III, V, VI, and VII have multiple peaks (endotherms and exotherm) which 
illustrate transformation by heating via melting. (The presence of solvated morphologies or 
hydrated ones were excluded by TG, H
1
-NMR and elemental analysis. The drug substance has 
several solvates, but in this study it was dealt only with “real” polymorphs.) These four 
polymorphs furnish a common peak at around 232 °C which corresponds to Form II. The 
melting and recrystallization transformation could also be observed by hot-stage microscopy. 
Therefore five out of the eight polymorphs transformed to Form II by heating via melting 
(monotropy) or without it (enantiotropy). For Form IVa, two endothermic peaks are observed 
at 219 and 227 °C, whereas Form IVb gives only one endothermic peak at 227 °C, which 
indicates the transformation caused by heating from Form IVa to IVb. The possibility of Form 
IVa being a solvated or hydrated form of Form IVb was also excluded in the same way as 
presented above.  
 
Table 7 The relevant DSC data on the 8 polymorphs 
Form 
T1 
(°C) 
ΔH 
(J/mol) 
T2 
(°C) 
ΔH 
(J/mol) 
T3 
(°C) 
ΔH 
(J/mol) 
T4 
(°C) 
ΔH 
(J/mol) 
I 231.4 -30485.96 – – – – – – 
II 232.0 -57561.94 – – – – – – 
III 214.3 -44675.68 219.1 +4089.51 231.8 -15184.30 – – 
IVa 218.7 -36793.19 226.6 -12144.97 – – – – 
IVb 227.3 -30615.69 – – – – – – 
V 130.9 -6603.75 174.8 +28904.52 233.4 -48610.75 – – 
VI 171.4 -15388.15 178.3 +18458.37 231.0 -54238.45 – – 
VII 184.0 -16320.96 188.3 +13053.06 215.4 -605.40 231.4 -22411.97 
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Fig. 9 The DSC curves of the eight polymorphs 
Dissolution rate study 
Dissolution rate study was an additional analytical investigation to distinguish the polymorphs 
generated. Particle size has effect on solubility and dissolution rate, therefore unified particle 
size is required. Despite of it, in our case there were clear differences in the dissolution 
between the different polymorphs which was not related to the particle size. In the developped 
dissolution medium, the rates could be well distinguished (Fig. 10). The fastest dissolution 
and the largest amount of dissolved compound were seen for Form V, whereas Form III 
displayed the slowest dissolution, but the lowest amount dissolved belonged to Form IVa. At 
Forms IVa and IVb a “burst effect” was observed at the beginning of the curve. This is in 
connection with the small particle size of these two polymorphs. After the 2 h dissolution 
examination the undissolved remaining of the eight polymorphs were checked by XRPD and 
no change in the polymorphic forms could be detected in this special dissolution medium. 
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Fig. 10 The extents of dissolution of the 8 polymorphs 
 
Conclusion 
Eight polymorphs for the compound were generated by a polymorph-screening protocol and 
distinguished by several analytical methods (light microscopy, SEM, Raman-spectroscopy, 
XRPD and DSC). A special dissolution medium for the screening of our polymorphic 
modifications was also developed. 
5.2. Relative stability examinations 
The relative stabilities of the polymorphs generated were investigated by three different 
analytical methods. All the solids could be stored without any change in morphology for at 
least 2 years. 
Slurry conversion  
When the ethanol suspensions were slurried at room temperature Forms I (in 4 days), V (in 17 
days), VI (in 10 days) and VII (in a few minutes) turned into Form III, whereas Forms II, III, 
IVa and IVb did not undergo any change within 130 days. At 50 °C, Form I was transformed 
to Form III (in 3 days), and Form III was transformed to Form IVb. The other forms 
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investigated (Forms II, IVa and IVb) remained unchanged during the investigation time (31 
days). At 70 °C, Form I turned into Form II, Form III into Form IVb, and Form IVa into Form 
IVb, while Forms II and IVb did not change during the investigated period (12 hours).  
When the polymorphs of the model drug were slurried in silicone oil at 200 °C, only Forms I 
and III turned into Form II. As expected (due to the generation of Form IVb), Form IVa 
changed into Form IVb. The other forms were not investigated. No interchange was observed 
between Forms II and IVb. 
 
Variable-humidity and temperature X-ray powder diffractometry 
The in situ VH-XRPD analyses did not revealany changes in the eight polymorphs. All of 
them were stable in the range 20-80 RH% and at 20 RH% in the repeated measurements. 
Neither the appearance of new reflection peaks nor intensity differences were detected, 
independently of whether the RH in the measuring chamber was increased or decreased.  
By contrast, the in situ VT-XRPD investigations yielded interesting results as concerns the 
polymorph transformation screening process. The intensities of the diffraction peaks of 
Form I decreased continuously during heating. The transformation of Form I started at about 
155 °C and was completed at about 190 °C (Fig. 11). After cooling back, the intensities of the 
diffraction peaks were slightly increased as compared with those of the sample measured at 
200 °C. The result of the transformation was Form II. The volume change caused by the 
temperature change resulted in slight shifts in the reflection peaks. A similar phenomenon was 
observed in the examination of each polymorph. 
 
Fig. 11 2D VT-XRPD diffractogram of Form I in the interval 30-200 °C 
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The temperature increase did not cause any phase transition of Form II; this polymorphic 
form remained stable until melting at 230 °C and after cooling back to 20 °C (Fig. 12). The 
VT-XRPD investigation indicated that this form was the stable one, and this was confirmed 
by DSC studies. 
 
 
Fig. 12 2D VT-XRPD diffractogram of Form II in the interval 30-200 °C 
 
The phase transition of Form III started at about 215 °C. After recooling, the new low-
intensity reflection peaks measured at 230 °C were increased significantly; Form II was 
identified. The shift in the lower-intensity reflection peaks at 2θ values of about 16-17° and 
the higher-intensity peaks at 2θ values of around 25° started at 160 °C, which indicated the 
earlier onset of this phase transition with some content of Form I (Fig. 13).  
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Fig. 13 2D VT-XRPD diffractogram of Form III in the interval 30-230 °C 
 
Increase of the temperature did not cause any changes in the Form IVa and IVb polymorphs 
up to 225 °C. Further increase of the temperature resulted in the melting of these samples, and 
after cooling back to 30 °C the samples became amorphous. Repeated measurements on the 
following day verified the persistence of the amorphous form. Because of the limitations of 
the VT-XRPD instrument, a sufficiently high temperature for the transformation of Form IVa 
to Form IVb could not be attained. During the heating of Form V, the diffraction peaks 
disappeared at about 145 °C. Thermomicroscopic studies confirmed that this phenomenon 
was caused by the melting process. Crystallization of the melt started at about 150 °C. The 
diffractogram of this new form (Intermediate I) differed from that of any other polymorph. 
During further heating of the material, a phase-transition process started at about 190 °C, 
resulting in a second new form (Intermediate II), and Form II finally crystallized at about 
220 °C. The diffraction peaks of the material cooled down to 20 °C were those of pure Form 
II (Figs 14 and 15).  
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Fig. 14 2D VT-XRPD diffractogram of Form V in the interval 30-230 °C 
 
 
Fig. 15 VT-XRPD diffractograms of Form V at several temperatures 
 
During the heating of Form VI, two phase-transition processe were detected, with onset 
temperatures of about 175 °C and 190 °C. The result of the first process was the previously 
detected Intermediate I, while the second series of peaks were those of Form II (Fig. 16). 
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Fig. 16 2D VT-XRPD diffractogram of Form VI in the interval 30-230 °C 
 
Finally, similarly to Form I, Form VII was transformed to Form II. The onset temperature of 
the phase transition was about 190 °C.  
Intermediates I and II could not be prepared in this investigation: although the heating was 
stopped at the given temperature, the transformation process continued. These two forms are 
unstable forms; all attempts to isolate them resulted in the stable Form II. 
Differential scanning calorimetry 
DSC investigations of all the polymorphic forms were performed at several heating rates. The 
results confirmed the findings of the XRPD investigations. The DSC studies carried out at 
different heating rates led to different results. Both the low (1 °C min-1) and the high (30 °C 
min
-1
) heating rate studies provided additional information on the phase-transition processes. 
The polymorph phase-transition peak of Form I could not be detected at low heating rate. 
However, a heating rate of 30 °C min-1 gave rise to a small exothermic peak at an onset 
temperature of 190 °C, which indicated that Form I was transformed into the more stable 
Form II. It was also observed that a higher heating rate generally caused the peaks to shift 
towards higher temperatures (Fig. 17). A similar phenomenon was observed for Form VII. 
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Fig. 17 DSC curves of Form I at different heating rates 
 
Depending on the heating rate, the DSC curves of Form II contained one endothermic peak at 
about 231-235 °C, which corresponded to the melting point of the most stable Form II. 
The phase-transition process of Form III to Form II was seen in a DSC curve at a lower 
heating rate (an endothermic peak at 213 °C and an exothermic peak at 214-215 °C). These 
processes could not be distinguished at the highest heating rate. The slow phase-
transformation process observed between 160 and 215 °C in the XRPD investigations was not 
detected in the DSC curves (Fig. 18) 
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Fig. 18 DSC curves of Form III at different heating rates 
 
In the DSC curves of Form V, the endothermic peak of melting was identified at about 132-
146 °C. At heating rates of 1 and 10 °C min-1, only the first phase-transition process was 
observed, which shifted towards higher temperatures on increase of the heating rate. The two 
phase-transition processes were seen only in the DSC curve at higher heating rate (Fig. 19). 
The phase-transition process of Form VI was detected in the DSC curve at a heating rate of 
10 °C min-1. The endothermic and exothermic pair at about 178 and 186 °C corresponded to 
the appearance of Intermediate I. The phase transition was not detected at a heating rate of 
1 °C min-1, while the subprocesses could not be separated at 30 °C min-1. 
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Fig. 19 DSC curves of Form V at different heating rates 
 
The MTDSC investigations did not provide more information on the relative stability of the 
polymorphs, and these results are therefore not presented in my PhD work. 
The enthalpies of Forms III, IVa, VI and VII were merely estimated, in view of the inability 
to obtain a single melting endotherm. The enthalpy of the melting endotherm for Form II 
proved to be the highest, and that of Form V the lowest (Table 7). Form II was not 
transformed to Form IVb or vice versa. 
Conclusion 
During the relative stability studies, the isothermal suspension equilibration and VT-XRPD 
methods led to different phase-transformation processes for some polymorphic forms. These 
phase-transition processes were confirmed by DSC studies carried out at different heating 
rates. The VT-XRPD investigations demonstrated the formation of two new unstable 
intermediate forms (from Forms V and VI). Forms IVa and IVb resulted in amorphous 
materials. Variation of the relative humidity did not influence the polymorphic 
transformations. It was concluded that Forms I, III, IVa, V, VI and VII are metastables, while 
Form IVb has almost the same stability as that of Form II because the transformation of Form 
IVb to Form II (and vice versa) has not been achieved to date. The enthalpy data, the 
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isothermal suspension equilibration investigations and the XRPD results confirmed that the 
thermodynamically stable polymorph is Form II. 
5.3. The influence of sucrose esters on the polymorphism of the model drug 
In the first five samples evaluated, the ratio of the model drug and the SE was 1:1. In each 
case, XRPD was used to identify the forms and to compare the samples containing SE with 
the pure polymorphs. Two SEs, sucrose laurate L 595 (HLB 5) and sucrose oleate O 1570 
(HLB 15), were found to modify the original Form IVa to Form III (Fig. 20). The other three 
selected SEs (S 370, S 1570 and D 1216) did not affect the polymorphism. 
In the second step, the influence of L 595 and O 1570 on the polymorphism was examined at 
four other concentration ratios. Both SEs gave the same results: the transformation of Form 
IVa to Form III occurred except when the quantity of the SE was 4 times that of the model 
drug in the sample. In that case, no characteristic peaks were seen in the X-ray powder 
diffractograms, which can be explained by the crystallization-inhibiting property of these SEs. 
 
Fig. 20 The XRPD patterns of the samples crystallized in the presence of SE O-1570 or L-595 
compared with the original Forms III and IVa 
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6. SUMMARY 
A polymorph screening investigation on a failed drug candidate was carried out to develop an 
appropriate method with which to distinguish the polymorphs generated after their dissolution, 
to investigate the relative stabilities of the polymorphs and to study the effects of SEs as 
additives during the screening process. 
A.  Preparation and identification of polymorphs 
A failed drug candidate obtained from Sanofi Pharmaceutical Company (Hungary) was 
investigated to explore its polymorphism by means of analytical examinations. The primary 
objective was to develop a polymorph screening method. Through crystallization and 
transformation methods, eight polymorphs were obtained and were characterized by light 
microscopy, SEM, XRPD, DSC and Raman spectroscopy. The different polymorphs exhibit 
different solubilities, which affects the bioavailability of the drug, and it is therefore important 
to perform dissolution studies with the different polymorphs. Because of the poor water-
solubility of the model drug, a special dissolution medium was developed in which the eight 
pure polymorphs could be well distinguished.  
XRPD is always the definitive method for the identification of polymorphs, but in some cases 
(Forms IVa and IVb) other analytical examinations were also required to characterize the 
individual forms. 
B. Analysis of the polymorph changes 
After the preparation and structural characterization of the polymorphs, their relative 
stabilities were also studied by an isothermal suspension equilibration method, VH-XRPD, 
VT-XRPD and DSC.  
For the isothermal suspension equilibration study the Avantium Crystal 16 automatic 
laboratory reactor system was complemented with XRPD to identify the morphologies. Its 
main advantage that the effects of solvent- and temperature-mediated polymorphic 
transformations can be investigated. 
In DSC tests, the application of different heating rates is recommended in order to obtain 
appropriate information relating to the details of phase-transformation processes. The 
literature findings indicate that the use of MTDSC may also give additional data, but in our 
case it did not provide more information. 
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The model drug was not sensitive to humidity, and variation of the relative humidity therefore 
had no influence on the polymorphic transformations. 
The in situ VT-XRPD investigations yielded new routes in the polymorph transformation 
screening process. Two new unstable intermediate forms appeared during the heating of 
Forms V and VI, though they could not be prepared by crystallization. Overall, it may be 
noted that VT-XRPD is a very useful in situ technique for the analysis of phase-transition 
processes. The results of the relative stability studies are presented in a flowchart (Fig. 21). 
 
 
Fig. 21 Flowchart of phase-transition processes 
 
C. The influence of SEs on polymorphism 
Finally, different SEs were studied from the aspect of their HLB values during the 
crystallization of the polymorphs to demonstrate their polymorph-changing effects. Two of 
the SEs used modified the original polymorphic form, and this modifying effect was 
demonstrated at different concentrations. This property of the SEs does not depend on the 
HLB value. 
D. Practical relevance of the results 
The results presented in this thesis furnish information that can be utilized in the polymorph 
screening of drug candidates and generic APIs. During the development of pharmaceuticals, it 
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is essential to investigate polymorphism for both economic and therapeutic reasons. The 
accurate establishment of thermodynamic stability relations is also very important, because 
unexpected polymorphs can appear. VT-XRPD can be a very useful technique for such 
stability studies. 
In the course of the polymorph screening process, it is sufficient to use only conventional 
crystallization methods, where the solvent and the temperature affect the formation of the 
crystals. The effects of the different additives used during the pharmaceutical production, and 
especially the surfactants, such as the SEs, must also be considered. The use of SEs in the 
pharmaceutical industry is increasing, because of their advantageous properties, such as 
solubility enhancement or emulsification. As this PhD work reveals, these commonly used 
additives can influence polymorphic phase-transformations, which can lead to undesirable 
changes in the product. 
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This study focused on an investigation of the applicability of sucrose laurate as surfactant in solid dis-
persions. Although this surfactant has a US Drug Master File, it has not been used so far in internal
pharmaceutical products. High drug-loaded solid dispersion systems consisting of gemﬁbrozil as amodel
drug and PEG 6000 as a carrier, with or without sucrose laurate (D1216), were prepared by the melting
method. Cytotoxicity studies onCaco-2monolayer cellswere also performed, in order to gain information
on the applicability of D1216 in oral formulations. The results showed that the presence of the surface-ucrose laurate
urfactant
olid dispersion
elt technology
ytotoxicity
active agent did not affect the solid-state characteristics of the model drug signiﬁcantly. A markedly
improved dissolution of gemﬁbrozil from the ternary solid dispersion systems was observed as com-
pared with the binary solid dispersion systems. The optimum concentration range of the D1216 in the
formulations was determined to be 5–10%. The effective ﬁnal concentrations of D1216 in the dissolution
experiments proved to be non-toxic towards CaCo-2 cells. The results suggest the potential use of D1216
armacaco-2 cells
emﬁbrozil
EG 6000
in innovative internal ph
The poor water solubility of drug substances and their low
ates of dissolution in the aqueous gastrointestinal ﬂuids often lead
o insufﬁcient bioavailability, and this remains a problem to the
harmaceutical industry. Solid dispersions of hydrophobic drugs
n water-soluble carriers have attracted considerable interest as a
eans of improving dissolution behaviour, and hence enhancing
ioavailability. Water-soluble carriers such as high-molecular-
eight polyethylene glycols (PEGs) and polyvinylpyrrolidones
PVPs) have been most commonly used for solid dispersions
Bikiaris et al., 2005; Craig and Newton, 1991; Leuner and
ressman, 2000; Saharan et al., 2009; Serajuddin, 1999). The use
f surfactants with solubilizing properties, such as polysorbates,
oloxamers, Gelucires (polyethylene glycol glycerides), sodium
auryl sulfate or vitamin E TPGS have also attracted consider-
ble interest recently (Dehghan and Jafar, 2006; Jagdale et al.,
010; Liu and Wang, 2007; Mura et al., 1999; Okonogi and
uttipipatkhachorn, 2006; Owusu-Ababio et al., 1998; Sethia and
quillante, 2002; Vasconcelos et al., 2007). As described in the
eview by Vasconcelos et al. (2007), the third-generation solid
ispersion systems contain a surfactant carrier, or a mixture of
morphous polymers and surfactants as carriers. These third-
eneration solid dispersions are intended to achieve the highest
egree of bioavailability for poorly soluble drugs. The inclusion
∗ Corresponding author. Tel.: +36 6254 5572; fax: +36 6254 5571.
E-mail address: revesz@pharm.u-szeged.hu (P. Szabó-Révész).
378-5173/$ – see front matter © 2011 Elsevier B.V. All rights reserved.
oi:10.1016/j.ijpharm.2011.03.033eutical formulations.
© 2011 Elsevier B.V. All rights reserved.
of surfactants in the solid dispersions may help to avoid drug
recrystallization and to stabilize the systems (Vasconcelos et al.,
2007).
Sucrose esters (SEs) are widely used in the food and cosmet-
ics industries, and there has recently been great interest in their
applicability indifferent pharmaceutical ﬁelds. They arebiodegrad-
able, natural, non-ionic surface-active agents consisting of sucrose
as hydrophilic moiety and fatty acids as lipophilic groups (Abd-
Elbary et al., 2008; Csóka et al., 2007; GanemQuintanar et al., 1998;
Okamoto et al., 2005; Otomo, 2009; Ntawukulilyayo et al., 1993;
Shibata et al., 2002).
In an earlier study we investigated, the structure and ther-
mal behaviour of SE in order to predict their applicability in hot
melt technology (Szu˝ts et al., 2007). Our results revealed that SEs
are semicrystalline carriers, with both amorphous and crystalline
regions. During the preparation of solid dispersions, the drugs are
built into the amorphous phases of the SEs (Szu˝ts et al., 2008). In
melt technology,mainly the lipophilic SEsmay be suggested as car-
riers. They display characteristic melting, whereas SEs with high
or moderate HLB values only soften during heating (Szu˝ts et al.,
2007). It has also been found that hydrophilic SEs exhibit gelling
behaviour at body temperatures, which can inﬂuence the drug
release (Szu˝ts et al., 2010a,b). In view of these results, the appli-
cability of hydrophilic SEs alone as carriers in hot melt technology
is not suggested. Dispersion or dissolution of the drugs in the soft-
ened SEs is difﬁcult, and a high amount of swelling SEs can reduce
the rate of dissolution of a drug.
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state in the solid dispersion system. However, the intensity of the
peaks of crystalline GEM in the solid dispersions was signiﬁcantly
lower than that of the intact drug, indicating a lower degree of
crystallinity of GEM in the binary solid dispersion system (inten-08 A. Szu˝ts et al. / International Journ
The aim of the present study was to evaluate the applicabil-
ty of hydrophilic sucrose ester as surfactant in third-generation
olid dispersion systems together with a polymer. As carrier, the
ommonly used PEG 6000 was chosen, with which the hydrophilic
HLB=16) sucrose laurate showed the best miscibility among
he evaluated sucrose esters (sucrose-stearate, -palmitate and -
aurate). Although this surfactant has a US Drug Master File, it
as so far not been used in internal pharmaceutical products. In
his work, studies on the cytotoxicity of sucrose laurate on Caco-2
onolayer cells were also performed, in order to gain information
n its availability in oral formulations.
Gemﬁbrozil (GEM), a poorly water-soluble (29.1g/ml at
H=6.2±0.1) model drug, was supplied by TEVA (Hungary).
EG 6000, the carrier used in our experiments, was from Hun-
aropharma (Hungary). Sucrose laurate D1216 (HLB=16) was
indly provided by Harke Pharma GmbH (Germany).
During the sample production, 40% w/w of GEM was always
pplied. In the case of the binary systems, PEG 6000 was heated
t 70 ◦C in a sand bath and, after melting, the appropriate amount
f GEM was added. In dispersions incorporating surfactant (1%, 5%,
0% or 15%w/w), D1216was dissolved in themelted carrier prior to
he addition of GEM. The molten mixture was stirred manually for
5min, to achieve homogeneous dispersion of the drug. The melts
ere quickly cooled to−10 ◦C in a freezer, afterwhich the solidiﬁed
amples were pulverized in a mortar and sieved to 200m.
The physical states of the GEM in the different samples were
valuated by XRPD with a Miniﬂex II X-ray Diffractometer (Rigaku
o. Tokyo, Japan), where the tube anodewas Cuwith K=1.5405 ´˚A.
atterns were collected with a tube voltage of 30kV and a tube
urrent of 15mA in step scan mode (4◦/min). The instrument was
alibrated by using Si.
The release of the model drug was studied by using Phar-
atest equipment (Hainburg, Germany) at a paddle speed of
00 rpm. 100ml artiﬁcial enteric juice with a pH of 6.8 (±0.05)
t 37 ◦C (±0.5 ◦C) was used. The concentration of GEM was
etermined spectrophotometrically at 276nm (Unicam UV/vis
pectrophotometer). The dissolution experiments were conducted
n triplicate.
The statistical test ANOVA was used to compare the results of
issolution data. The difference between samples was deemed sta-
istically signiﬁcant if the 95% conﬁdence intervals for the means
id not overlap (p<0.05).
Theeffect ofD1216on living cellswas testedbyusing thehuman
olon carcinomacell lineCaCo-2 (ATCC,USA), amodel of the intesti-
al epithelium (Breemen and Li, 2005). Cells were grown in Eagle’s
inimal essential medium (MEM, Invitrogen) supplemented with
5% foetal bovine serum (Lonza, Switzerland) and 1% Na-pyruvate
Sigma, Hungary). Conﬂuent monolayers were obtained in 96-well
lates (Orange Scientiﬁc, Belgium)3days after cell seeding. For tox-
city experiments, Dulbecco’s Modiﬁed Eagle’s medium (DMEM)
ithout phenol red was used as assay medium. Two different cyto-
oxicity tests were performed. The lactate dehydrogenase (LDH)
ssaydetects cell damage anddeathbymeasuring the release of the
ytoplasmic enzyme LDH from cells due to plasma membrane dis-
uption. The LDH levels in culture medium were determined with a
ommercially available kit (Cytotoxicity Detection Kit LDH, Roche,
witzerland). An increase in the number of dead or membrane-
amaged cells results in an increase in LDH activity in the cell-free
ulture supernatant. Cytotoxicity was calculated as a percentage of
he total LDH release from cells treated with 1% Triton X-100 as
etergent. The MTT test measures cell viability, because only living
nd metabolically active cells can convert the yellow tetrazolium
alt (MTT, Sigma M5655) into insoluble purple formazan crystals.
he extent of dye conversion was determined spectrophotometri-
ally by measuring the absorbance at 570nm. In the MTT assay, aFig. 1. X-ray power diffraction data of pure materials and solid dispersion systems.
decrease in dye reduction correlates to the cell damage. Viability
was calculated as a percentage of the number of untreated con-
trol cells. All experiments were repeated at least three times; the
number of parallel wells for each treatment and time point varied
between 4 and 8.
An earlier study revealed that the hydrophilic sucrose stearate
and sucrose palmitate do not melt during heating, but only soften
(Szu˝ts et al., 2007). In consequence of this thermal behaviour, the
distribution of a drug in their melts is difﬁcult, and can result
in an inhomogeneous product. Hence, in the present study, the
applicability of sucrose laurate as a surfactant was examined in
a third-generation solid dispersion system. The solid dispersions
were prepared by the melting method, containing GEM as model
drug and PEG 6000 as carrier, with or without D1216 as surfactant.
In the ternary solid dispersion systems, when D1216 was used up
to 15%, a homogeneous melt could be formed.
Intact GEM and PEG 6000 displayed identical sharp XRPD peaks
at various values of 2, while the X-ray pattern of D1216 exhib-
ited an amorphous, broad halo (Fig. 1). In order to determine the
crystallinity degree of drug in solid dispersions, the intensity of
the most characteristic peak of GEM (intensity: 7767 at 2 =12.06)
was evaluated in the various systems. The XRPD pattern of GEM
binary solid dispersions demonstrated the diffraction peak of the
crystalline drug. This suggested that GEM existed in the crystallineFig. 2. Dissolution curves of GEM and solid dispersion systems containing various
concentrations (0, 1, 5, 10 and 15%) of D1216 as surfactant.
A. Szu˝ts et al. / International Journal of Pharmaceutics 410 (2011) 107–110 109
F itheli
f
s
s
p
T
t
p
5
2
o
t
i
D
(
5
G
t
a
D
f
s
d
l
t
a
d
c
e
t
i
i
T
i
t
d
w
6
C
o
c
(
t
s
r
oig. 3. Cytotoxicity measurements on various concentrations of D1216 on Caco-2 ep
ollowing treatment for 4h (means± SD, n=8–4).
ity: 2500 at 2 =11.52). As the drug was highly loaded into the
olid dispersion, some of the GEM molecules were molecularly dis-
ersed, and a higher amount of GEMexisted in the crystalline state.
he XRPD patterns of the ternary solid dispersions were similar to
hose of the binary system (intensities of the most characteristic
eak of ternary systems: 2070 at 2 =11.64 (GEM-PEG-D1216 40-
5-5), 1950 at 2 =11.56 (GEM-PEG-D1216 40-50-10) and 2452 at
 =11.52 (GEM-PEG-D1216 40-45-15) (Fig. 1). The incorporation
f D1216 up to 15% had no effect on the XRPD pattern of GEM in
he solid dispersion system.
Fig. 2 illustrates that the D1216 in samples resulted in signif-
cantly higher GEM release than that of started GEM. For the 1%
1216-containing solid dispersion, the drug release was similar
p>0.05) that to form the binary solid dispersion system, whereas
% SE resulted in signiﬁcantly faster release. In this case, 90% of the
EM had dissolved after 10min. With increasing content of D1216,
he dissolution rate increased further. 100% GEM release could be
ttainedafter10minon theuseof10%D1216 (Fig. 2). Increaseof the
1216 concentration from 10% to 15% did not result in signiﬁcantly
aster release. Accordingly, 5–10% D1216 seems to be optimum for
olid dispersions of GEM.
PEGs have beenused extensively as carriers for solid dispersions
ue to their favourable solution properties, low melting points and
ow toxicity. Thanks to these characteristics, they are approved by
he FDA for internal consumption.
Besides improving dissolution, surfactants can also enhance
bsorption, thereby increasing the bioavailibility of poorly soluble
rugs (Deli, 2009). However, surfactants may be cytotoxic, which
an reduce their applicability in oral formulations (Dimitrijevic
t al., 2000; Ekelund et al., 2005; Kiss et al., 2010). In this study,
herefore, cytotoxicity measurements were made on the human
ntestinal epithelial cell line Caco-2 in order to determine the max-
mum non-toxic concentration of D1216 as absorption enhancer.
he cytotoxicity of various concentrations of D1216 in LDH tests
s shown in Fig. 3. The concentration of D1216 that caused no
oxicity after 1h was below 200g/ml. In the MTT studies, the
urationof treatmentwas4h, and signiﬁcant toxicitywasobserved
hen the D1216 concentration exceeded 100g/ml (Fig. 3). Above
00g/ml D1216, high toxicity occurred, resulting in the death of
aco-2 cells (Fig. 3).
Our dissolution studies shown, that applying 5–10% D1216 was
ptimum for GEM solid dispersions. In these formulations, the con-
entrations of D1216 in the dissolution media were 83.3g/ml
5% D1216) and 166.7g/ml (10% D1216), proved to be non-toxic
owards Caco-2 cells.
The cytotoxicity studies demonstrated similarly as with other
urfactants, that, when the internal applicability of sucrose lau-
ate is under consideration, the possible risk of the local effect
f an increased concentration in the microenvironment of theal cells by LDH release after treatment for 1h with D1216, and MTT dye conversion
gastrointestinal tract must be taken into account. It should be
noted that the SEs are widely used in different food products,
and their acceptable daily intake was set as 40mg/kg/day. Sucrose
laurate was not considered in that evaluation, but the Euro-
pean Food Safety Authority (EFSA) recently pointed out that
the current speciﬁcations should be changed to include sucrose
laurate (EFSA, 2010).
It can be concluded that the applicability of sucrose laurate in
third-generation solid dispersions prepared by melt technology
may be regarded as a good technique with which to accelerate the
dissolution of poorly soluble drugs such as GEM. The presence of
1–15% surface-active agent did not appear to affect the solid-state
characteristics of GEM signiﬁcantly. The in vitro dissolution studies
shown, that applying 5–10% D1216 was optimum to improve GEM
release from solid dispersions. In these formulations, the concen-
trationsof sucrose laurate in thedissolutionmediawere83.3g/ml
(5% D1216) and 166.7g/ml (10% D1216), proved to be non-toxic
towards Caco-2 cells.
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a  b  s  t  r  a  c  t
Polymorph  screening  is  currently  one  of  the  most  important  tasks for innovators  and  for  generic  com-
panies from  both  pharmaceutical  and  intellectual  property  rights  aspects.  The  different  polymorphs
have  different  physicochemical  properties,  such  as  the  crystal  polymorph-dependent  solubility  which
inﬂuences  the bioavailability.
A  former  drug  candidate  obtained  from  Sanoﬁ  Pharmaceutical  Company  (Hungary)  was  investigated
to  explore  its polymorphism,  to distinguish  the morphologies  generated  by analytical  examinations  and
to  investigate  their  relative  stabilities.  An Avantium  Crystal  16  automatic  laboratory  reactor  system  was
used for  the polymorph  studies  and the  studies  of  their dissolution.  Eight  polymorphs  were  obtained  by
crystallization  and  transformation  methods  then  characterized  by  XRPD,  DSC,  and  Raman  spectroscopy,issolution test scanning  electron  microscopy,  and  light  microscopy.  All  the  morphologies  could  be stored  in solid  without
any  form  transformation  for a long  time  (2 years  investigated).  According  to  the  ﬁrst  relative  stability
results,  Form  I, III,  IVa,  V, VI,  VII are  unambiguously  metastable  forms.  Form  II  and  IVb  have  similar
thermodynamic  stabilities,  that  were  higher  than those  of the  other  polymorphs.
A  special  dissolution  medium  was  developed  in  which  the  eight  polymorphs  showed  clear  differences
in  the  rate  of  dissolution.
. Introduction
Polymorphism, the ability of an element or compound to crys-
allize in more than one distinct crystal species [1], is a major
roblem that has been of considerable importance in the pharma-
eutical industry in the development of new drug candidates [2,3].
he different polymorphs exhibit different physical and physico-
hemical properties, such as habit, colour, density, melting point,
olubility, dissolution rate, etc. [4]. These differences may  affect
he pharmaceutical processing, the stability of the drug product,
he bioavailability and the toxicity, and thereby the therapeu-
ic efﬁcacy of the drug substance [5]. Furthermore, each crystal
hase can be protected by patents [6], which is very important
or the innovator. During the polymorphism screening process, it
s necessary to investigate the relative stability, because mostly
hermodynamically stable forms are used in the drug products
7].
The most common polymorph screening methods are crys-
allization from melt, vapour, and solutions through cooling or
vaporating the solvent, addition of an antisolvent to the solution
8], or slurrying the solid active pharmaceutical ingredient for an
xtended period of time at different temperatures [9].
∗ Corresponding author. Tel.: +36 62 545 571; fax: +36 62 545 571.
E-mail address: aigner@pharm.u-szeged.hu (Z. Aigner).
731-7085/$ – see front matter ©  2013 Elsevier B.V. All rights reserved.
ttp://dx.doi.org/10.1016/j.jpba.2013.06.002© 2013 Elsevier B.V. All rights reserved.
The outcome of a crystallization can be affected by factors such
as the solvent (viscosity, polarity), the rate of creating supersa-
turation (cooling, adding or evaporation rate), or initial solution
concentration [10]. Other crystallization conditions, e.g. the rate of
stirring, different mechanical processes (e.g. ultrasound effect) or
different additives, may  also inﬂuence the ﬁnal crystal polymorph
obtained.
The most common methods for the characterization of the
various polymorphs are powder X-ray diffractomerty (XRPD),
single-crystal X-ray diffractometry (SC-XRD), differential scanning
calorimetry (DSC), optical and electron microscopy, infrared (IR),
near-infrared (NIR), Raman, and more recently solid-state nuclear
magnetic resonance spectroscopy (ssNMR) [11–16].
In case of polymorphism the relative stability and the trans-
formation conditions of the different polymorphs must be
investigated [17]. Polymorphic transformations between crys-
talline modiﬁcations of an active pharmaceutical ingredient in,
e.g. crystallization, heating/cooling studies and milling have been
already characterized by various solid-state analytical methods
[18]. An Avantium Crystal 16 automatic laboratory reactor sys-
tem was used for such investigations. This medium-throughput
polymorph and salt screening technology performs 16 parallel
crystallization experiments, and provides an estimate of solu-
bility by using turbidity measurements [19]. With this reactor
system, the solubility and supersolubility curves can also be
determined [20].
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The model compound of this study was a former drug candidate
btained from Sanoﬁ Pharmaceutical Company. Here, a description
f the polymorphism of a drug candidate is presented without using
dditives during the generating process. The polymorphs were
enerated by crystallization methods (cooling, evaporation) and
eating transformation, furthermore the modiﬁcations obtained
ere distinguished by means of various analytical examinations.
or the dissolution study, a special dissolution medium was  devel-
ped in which the different polymorphs could be distinguished.
. Experimental
.1. Materials
The model drug used was 3-[2-({[1-(2-cyclohexylethyl)-
-(2,5-dimethoxy-4-methylphenyl)-1H-1,2,4-triazol-3-
l]amino}carbonyl)-6-methoxy-4,5-dimethyl-1H-indol-1-
l}propanoic acid (Fig. 1). The crystallization of the various
olymorphic forms was achieved with different organic sol-
ents of analytical grade: acetonitrile, methanol, 96% ethanol,
bs. ethanol, isopropanol, acetone, 2-butanone, toluene (Merck,
udapest, Hungary), dichloromethane, ethyl acetate, butyl
cetate, chloroform, 1,4-dioxane (Reanal, Budapest, Hungary), and
etrahydrofuran (Aldrich, Budapest, Hungary).
.1.1. Preparation of polymorphs by crystallization
Different techniques were used for the preparation of the poly-
orphs (Table 1):
Crystallization by shock cooling:  The raw material was dissolved
t the boiling point of the solvent to give a saturated solution which
as then diluted with a small amount of the solvent. The hot solu-
ion was ﬁltered into a vial immersed into crashed ice.
Crystallization by slow cooling: The same process of dissolution
as used, but the ﬁltered, hot solution was cooled down slowly
−3 ◦C/h).
Crystallization by slow evaporation: The products were the dried
esidues of the clear ﬁltrates of the samples prepared by shock
ooling.
able 1
he techniques and conditions used for preparation of the polymorphs.
Form Method Solvent 
I Crystallization 96%, abs. ethanol 
II  Heating – 
III  Crystallization Isopropanol, 2-butanone, butylacetate, 
IVa  Crystallization Methanol 
IVb  Heating – 
V  Crystallization Chloroform 
VI  Crystallization Acetone, methanol, dichloromethane, 1
VII  Crystallization Acetonitrile e former drug candidate.
2.1.2. Preparation of polymorphs by heating transformation
Through heating processes at various temperatures for different
periods of time, the polymorphs generated by crystallization could
be transformed to other forms.
2.2. Investigation methods
2.2.1. Identiﬁcation of crystalline forms of samples
2.2.1.1. Powder X-ray diffractometry. XRPD spectra were recorded
with a BRUKER D8 Advance diffractometer (Bruker AXS GmbH,
Karlsruhe, Germany) system with Cu K1 radiation ( = 1.5406 A˚)
over the interval 2.5–40◦/2. The measurement conditions were as
follows: target, Cu; ﬁlter, Ni; voltage, 40 kV; current, 40 mA; time
constant, 0.1 s; angular step 0.016◦. Detecor: NaI (Tl) scintillation
detector.
2.2.1.2. Differential scanning calorimetry. DSC curves were
obtained by a Mettler Toledo DSC27HP apparatus (Mettler-Toledo
AG, Greifensee, Switzerland) under the following conditions:
sample weight: about 2–3 mg;  sample holder: aluminum crucible
(40 L) with lid; nitrogen ﬂow rate: 100–150 mL/min; heating
rate: 10 ◦C/min from 25 ◦C up to 250 ◦C. In every case, samples
were held at 25 ◦C for 10 min  before recording.
2.2.1.3. Raman spectroscopy. Raman spectra were recorded at
room temperature by using a Bruker SENTERRA Dispersive Raman
Microscope (Bruker Optik GmbH, Ettlingen, Germany) equipped
with Nd-YAG (532 nm)  and diode (785 nm)  excitation lasers and
a cooled CCD detector. The system was ﬁtted with a motorized XYZ
sample stage. The equipment was  controlled by OPUS 6.5 software
(Bruker Optik GmbH, Ettlingen, Germany). Samples were analyzed
on glass slides.
Following a parameter optimization process, the samples were
measured by Nd-YAG (532 nm)  laser at a laser power of 10 mW.
An integration time of 5 s, and 3 scans were used for each mea-
surement, and spectra were collected over the Raman shift range of
3500–60 cm−1 at a resolution of 3–5 cm−1. The microscope magniﬁ-
cation was  200× and a certain crystal was selected for analysis with
Conditions
Shock cooling
160 ◦C/6 h (from Form I)
ethylacetate, toluene Shock cooling
Shock cooling
205 ◦C/6 h (from Form IVa)
Shock cooling, slow cooling, slow evaporation
,4-dioxane Shock cooling, slow cooling, slow evaporation
Shock cooling
l and Biomedical Analysis 84 (2013) 177– 183 179
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Table 2
The characteristic diffraction peaks of the 8 polymorphs.
d ( ´˚A) 2 (◦) Intensity (counts) I/I1 (%)
Form I 20.054 4.403 10.30 100.0
10.388 8.505 0.61 5.9
6.64  13.319 0.92 8.9
5.926 14.937 0.89 8.7
4.995 17.744 1.00 9.7
4.156 21.360 6.71 65.0
3.3983 22.300 2.58 25.0
3.463 25.707 1.01 9.8
2.605 34.405 0.49 4.7
2.429 36.983 0.40 3.9
Form II 18.386 4.802 24.50 100.0
8.212 10.756 7.99 32.6
6.023 14.696 4.10 16.7
5.694 15.549 4.98 20.4
5.085 17.428 4.32 17.6
4.587 19.336 5.51 22.5
4.387 20.225 6.25 25.5
4.117 21.570 4.85 19.8
3.684 24.139 14.40 58.7
3.562 24.977 3.35 13.7
Form III 10.715 8.245 16.30 100.0
9.579 9.224 0.71 4.4
9.125 9.685 1.56 9.6
8.419 10.498 1.59 9.8
8.043 10.992 0.78 4.8
4.207 21.099 2.09 12.9
4.038 21.995 2.49 15.3
3.636 24.465 0.98 6.0
3.572 24.903 1.47 9.0
2.908 30.719 0.66 4.0
Form IVa 12.531 7.048 2.28 34.6
10.005 8.831 2.09 31.8
8.304 10.645 1.93 29.3
6.276 14.100 3.03 46.0
5.329 16.622 2.27 34.5
4.816 18.408 3.16 48.0
4.448 19.947 1.95 29.7
4.166 21.309 6.59 100.0
3.617 24.592 3.05 46.3
3.486 25.533 2.51 38.2
Form IVb 12.543 7.042 72.40 53.1
10.041 8.799 94.50 69.3
8.286 10.669 81.20 59.6
6.304 14.037 81.90 60.1
5.342 16.582 82.10 60.3
5.186 17.083 78.50 57.6
4.444 19.962 72.70 53.4
4.175 21.263 136.00 100.0
4.120 21.550 72.70 53.4
3.627 24.521 62.30 45.7
Form V 19.665 4.490 0.41 5.1
16.458 5.365 8.01 100.0
Form VI 10.818 8.167 2.56 32.4
8.163 10.830 0.63 8.0
5.766 15.355 0.70 8.9
5.419 16.343 7.88 100.0
4.144 21.423 1.67 21.2
3.819 23.267 4.68 59.4
3.743 23.750 0.68 8.6
3.627 24.595 3.28 41.6
3.121 28.582 0.58 7.4
2.406 37.350 0.59 7.4
Form VII 17.004 5.193 14.30 100.0
10.306 8.573 8.61 60.3
9.715 9.096 8.50 59.5
8.833 10.006 2.81 19.7
6.208 14.255 4.92 34.4P. Láng et al. / Journal of Pharmaceutica
 50 m × 1000 m grating. Single Raman spectra of the individual
rystals were collected in each case.
.2.1.4. Scanning electron microscopy. The morphology of the par-
icles was examined by SEM (Hitachi S4700, Hitachi Scientiﬁc Ltd.,
okyo, Japan). A sputter coating apparatus (Bio-Rad SC 502, VG
icrotech, Uckﬁeld, United Kingdom) was applied to induce elec-
ric conductivity on the surface of the samples. The air pressure was
.3–13.0 mPa.
.2.1.5. Particle size analysis. The particle size distribution of the
rug candidate was measured by LEICA Image Processing and Anal-
sis System (LEICA Q500MC, LEICA Cambridge Ltd., Cambridge,
nited Kingdom). The particles were described in terms of their
ength, breadth, surface area, perimeter and roundness which is a
hape factor giving a minimum value of unity for a circle. This is cal-
ulated from the ratio of perimeter squared to area. The adjustment
actor of 1.064 corrects the perimeter for the effect of the corners
roduced by the digitization of the image.
oundness = Perimeter
2
4 ·  · Area · 1.064
.2.2. Physicochemical properties of the forms
.2.2.1. Dissolution examinations. Dissolution was studied by a
odiﬁed paddle dissolution apparatus (Pharmatest, Hainburg,
ermany) at a paddle speed of 100 rpm. 100 mL  of dissolution
edium was placed in a 37 ◦C (±0.5 ◦C) bath and the examination
as performed for 2 h. Because of the poor solubility of the model
rug, neither gastric acid nor intestinal ﬂuid could be used alone.
herefore, an appropriate dissolution medium had to be developed.
The preliminary examination of the model compound showed
hat its solubility depends on pH: at low pH (gastric acid) is
orse than at neutral pH (intestinal ﬂuid), therefore intestinal
uid (pH = 6.8) was chosen, but the dissolution even in intesti-
al ﬂuid was not up to 100%. As all the 8 polymorphs dissolved
ell in 96% ethanol, the optimum mixture of 96% ethanol: intesti-
al ﬂuid (pH = 6.8) was  found of a volumetric ratio of 3:7. The
oncentration of each polymorph solution was determined spec-
rophotometrically at 324 nm (Unicam UV/vis spectrophotometer,
nicam Limited, Cambridge, United Kingdom). The dissolution
xperiments were conducted in triplicate and standard deviation
as also calculated.
.3. Relative stability examinations
An Avantium Crystal 16 automatic laboratory reactor system
as used to investigate the relative stabilities of the different poly-
orphs. The organic solvents for the relative stability examination
ere chosen regarding to the solubility properties of each poly-
orph (very high, medium, and low solubility). First 96% ethanol
as applied for different periods of time at various temperatures.
. Results and discussion
.1. XRPD
XRPD is always the deﬁnitive method for the identiﬁcation
f polymorphs [4]. The XRPD patterns of the 8 polymorphs are
hown in Fig. 2. The characteristic diffraction peaks are presented in
able 2. The data in Table 2 indicate that the characteristic peaks are
ituated between 4 and 26 2 degree. All the 8 polymorphs (with
he exception of Forms IVa and IVb) exhibit clear XRPD differences,
ut these two forms can be well distinguished by other methods,
hough Form IVa and IVb were very similar to each other.
5.154 17.191 2.63 18.4
4.892 18.121 2.25 15.8
4.164 21.321 7.67 53.7
3.876 22.925 3.95 27.7
3.446 25.835 2.46 17.2
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TFig. 2. The XRPD patterns of the 8 polymorphs.
.2. DSC
The DSC curves and the relevant data of the 8 polymorphs are
hown in Fig. 3 and Table 3. The 8 forms give different DSC patterns,
xcept for Form I and II which display a single endothermic peak
t about 232 ◦C (under the DSC conditions, Form I is converted to
orm II). Without melting, the transformation of Form I–II could be
bserved by hot-stage microscopy.
Forms III, V, VI, and VII have multiple peaks (endotherms and
xotherm) which illustrate transformation by heating via melt-
ng. The presence of solvated morphologies or hydrated ones were
xcluded by TG, H1-NMR and elemental analysis. The drug sub-
tance has several solvates, but in this study it was dealt only with
real” polymorphs. According to the humidity XRPD results, the
olymorphs were stable in the interval 20–80% RH, no hydrated
orphologies occurred. These four polymorphs furnish a common
able 3
he relevant DSC data on the 8 polymorphs.
Form T1 (◦C) H (J/mol) T2 (◦C) H  (J/mol) 
I 231.4 −30485.96 – – 
II  232.0 −57561.94 – – 
III  214.3 −44675.68 219.1 +4089.51 
IVa  218.7 −36793.19 226.6 −12144.97 
IVb  227.3 −30615.69 – – 
V  130.9 −6603.75 174.8 +28904.52 
VI  171.4 −15388.15 178.3 +18458.37 
VII  184.0 −16320.96 188.3 +13053.06 Fig. 3. The DSC curves of the 8 polymorphs.
peak at around 232 ◦C which corresponds to Form II. The melt-
ing and recrystallization transformation could also be observed by
hot-stage microscopy. Therefore ﬁve out of the eight polymorphs
transformed to Form II by heating via melting (monotropy) or with-
out it (enantiotropy).
For Form IVa, 2 endothermic peaks are observed at 219 and
227 ◦C, whereas Form IVb gives only 1 endothermic peak at 227 ◦C,
which indicates the transformation caused by heating from Form
IVa to IVb. The possibility of Form IVa being a solvated or hydrated
form of Form IVb was  also excluded in the same way as presented
above.
3.3. Raman spectroscopy
Raman spectroscopy is an analytical technique that is widely
applied for the chemical and physico-chemical characterization
of solid compounds as it is a non-destructive method and needs
only minimal sample preparation. Furthermore, in contrast with IR
spectroscopy, it is not disturbed by the presence of water. Ramanof the molecules, but the material itself or its impurities may
cause background ﬂuorescence which makes the analysis difﬁcult
or sometimes impossible.
T3 (◦C) H (J/mol) T4 (◦C) H (J/mol)
– – – –
– – – –
231.8 -15184.30 – –
– – – –
– – – –
233.4 -48610.75 – –
231.0 −54238.45 – –
215.4 −605.40 231.4 −22411.97
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by shock cooling in chloroform are around 25 m,  with a nearlyFig. 4. The Raman spectra of the 8 polymorphs.
Raman spectroscopy generally has better spectral selectivity
for the distinction of polymorphic forms including the amorphous
tate) as the symmetric stretching linked to the carbon skeleton is
ore expressed than IR spectroscopy has.
There are clear differences at the ranges 3200–2800 cm−1 and
800–1000 cm−1 (Figs. 4 and 5). The spectra of Form I and Form IVb
emonstrate low intensities comparing to the other forms (5000
nd 1200 a.u. vs. 20,000–40,000 a.u.). Furthermore Form II and Form
Va exhibit slight ﬂuorescence behaviour.
Between 3200 cm−1 and 2700 cm−1 each of the polymorphs
xcept for Forms I and IVb gives a single peak at 2843 cm−1. Form
II has another peak at 3010 cm−1. Form III can be easily dis-
inguished by the single peaks at 3042 and 2966 cm−1. Form VII
as 3 discriminative peaks between 3100 cm−1 and 2950 cm−1
Fig. 4).
Between 1800 cm−1 and 900 cm−1 further differences can bebserved. Form V has unique peaks at 1677 cm−1, 1476 cm−1 and
036 cm−1 while Form VII also has singular peaks at 1694 cm−1,
542 cm−1, 1325 cm−1 and 1247 cm−1. Minor differences are to be
Fig. 6. The SEM pictures ofFig. 5. The Raman spectra of the 8 polymorphs.
seen at about 1550 cm−1. Characteristic peaks can also be found in
the range 1400–900 cm−1 (Fig. 5).
3.4. SEM
The SEM pictures (Figs. 6 and 7) reveal that the crystals of the
polymorphs present differences in size, morphology and surface.
Form III obtained by shock-cooling in isopropanol, 2-butanon, or
ethyl acetate gave mostly irregular trapezoid crystals with a smooth
surface around 50 m.  Form I (shock cooling in ethanol) resulted in
long needle-shaped crystals. When Form I was heated to 160 ◦C, the
transformation led to a new morphology. Form II contained pris-
matic crystals in size range of 25–60 m.  Form V crystals obtainedditrigonal morphology.
The morphology of Form IVa obtained by shock cooling in
methanol and Form IVb obtained by heating of Form IVa were
 Forms I, II, III and V.
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ery similar, involving slender ditrigonal and ditetragonal prisms.
he crystals of Form IVa were smaller than those of Form IVb. The
rystals of Form VI and Form VII were very irregular and varied in
ize.
.5. Particle size analysis
About 400 particles were analyzed by light microscopy. Table 4
resents the results. Most of the particles had sizes in the range
0–25 m.  The smallest particles were those of Form IVa, and the
argest were those of Form VI. Form I and II gave very similar aver-
ge results. Form V exhibited the smallest roundness value which
xplains the best dissolution proﬁle. Form II and IVb were prepared
y heating transforming one polymorph into another, and there
as no signiﬁcant difference in particle size..6. Dissolution examinations
As it is known, particle size has effect on solubility and dis-
olution rate, therefore uniﬁed particle size is required. Despite
able 4
he average results of the particle size analysis.
Form Length (m) Width (m) 
I Average 22.7 12.7 
SD±  13.7 6.6 
II  Average 22.5 13.1 
SD±  12.5 7.0 
III  Average 20.4 12.2 
SD±  13.8 8.7 
IVa  Average 10.4 4.6 
SD±  4.1 1.7 
IVb  Average 17.8 6.3 
SD± 11.4 3.3 
V  Average 20.3 14.3 
SD±  11.8 8.3 
VI  Average 109.8 63.5 
SD±  62.2 40.2 
VII  Average 31.2 20.0 
SD±  17.9 11.5 rms IVa, IVb, VI and VII.
of it, in our case there were clear differences in the dissolution
between the different polymorphs which was not related to the
particle size. In the special dissolution medium, the rate of disso-
lution could be well distinguished (Fig. 8). The fastest dissolution
and the largest amount of dissolved compound were seen for Form
V, whereas Form III displayed the slowest dissolution, but the low-
est amount dissolved belonged to Form IVa. At Forms IVa and IVb
a “burst effect” was  observed at the beginning of the curve. This is
in connection with the small particle size of these 2 polymorphs.
After the 2 h dissolution examination the undissolved remaining
of the 8 polymorphs were checked by XRPD and no change in the
polymorphic forms could be detected in this special dissolution
medium.
3.7. Relative stability examinationInvestigating the individual polymorphs in 96% ethanol, the
transformation of Forms I, V, VI, and VII could be observed to
Form III even at room temperature, while Forms II, III, IVa and IVb
remained unchanged during the investigated period (130 days).
Perimeter (m) Area (m2) Roundness
68.7 214.9 1.99
45.3 300.5 1.13
77.8 203.1 2.41
69.2 201.6 2.18
62.7 231.8 1.77
46.2 336.7 0.75
27.6 33.2 1.85
11.2 21.8 0.61
44.3 78.6 2.10
28.5 84.4 1.00
61.9 259.9 1.38
40.2 334.7 0.43
354.2 5348.4 2.12
279.0 5970.1 1.44
106.3 476.8 2.23
88.9 541.7 1.97
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orms III and IVa transformed to Form IVb at elevated tempera-
ure (50 ◦C and 70 ◦C). In 96% ethanol Form II and Form IVb did not
ransform at all.
The preliminary results of the relative stability examinations
emonstrated that the stability of Forms II and IVb are similar and
igher than those of the other polymorphs.
. Conclusion
Eight polymorphs for the compound were generated by a
olymorph-screening protocol and distinguished by several ana-
ytical methods (XRPD, DSC, Raman-spectroscopy, and SEM).
heir relative stability was investigated by an Avantium Crys-
al 16 automatic laboratory reactor system. A special dissolution
edium for the screening of our polymorphic modiﬁcations was
eveloped.
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The  effects  of solvents,  temperature  and  humidity  on the  stability  of  a former  drug  candidate  obtained
from  Sanoﬁ  (Hungary)  were  examined  by a slurry  equilibration  method,  variable  temperature  and
humidity  X-ray  powder  diffractometry  (VT/VH-XRPD)  and  differential  scanning  calorimetry  (DSC).  The
VH-XRPD  study  showed  that  all 8  polymorphic  forms  of  this  material  were  stable  in  the  interval  20–80
RH%.  The  VT-XRPD  measurements  indicated  that  all the polymorphs  except  Form  II underwent  changeseywords:
olymorphs
elative stability
T/VH-XRPD
SC
in  the  range  30–200 ◦C. The  stable  form  was  Form  II, though  Form  IVb  had  almost  the  same  stability.  The
investigation  demonstrated  that  VT-XRPD  is  a very  useful  in  situ method  for relative  stability  studies.
© 2014  Elsevier  B.V.  All  rights  reserved.hermodynamic stability
. Introduction
During pharmaceutical production, materials go through many
rocesses, such as compression, granulation, grinding, drying [1].
olymorphs have different lattice energies, and forms with higher
nergy tend to transform into forms with lower energy [2]. The stor-
ge conditions, such as humidity or temperature, affect the stability
f the crystal forms [3–7]. Characterization of the polymorphs gen-
rated and clariﬁcation of the thermodynamic stability relations
re important during the polymorphism screening process [2].
It was reported earlier that the rate of transformation of a form
n suspension depended on the temperature and its solubility in the
uspending medium used [2]. If polymorphs do not display distinct
ifferences in their enthalpies of fusion or/and no phase transi-
ion peak is found in the DSC curve [8], the enthalpies and melting
oints determined by DSC are not sufﬁcient for a detailed eval-
ation of transitions and thermodynamic stabilities. In that case,
he solubility data of the forms are especially important in the
nvestigation of the phase transitions of the various polymorphs
2].
Research, product usage and patent protection of pharmaceut-
cals can involve high importance being placed on polymorph
creening and the use of powder diffraction [9]. X-ray powder
iffractometry (XRPD) provides the most direct and deﬁnitive
∗ Corresponding author. Tel.: +36 62 545 571; fax: +36 62 545 571.
E-mail address: lang@pharm.u-szeged.hu (P. Láng).
ttp://dx.doi.org/10.1016/j.jpba.2014.09.020
731-7085/© 2014 Elsevier B.V. All rights reserved.identiﬁcation of polymorphs and can offer a means for the quantita-
tive analysis of polymorphic mixtures [10]. XRPD analysis based on
diffraction peak angles and the corresponding intensities is often
preferred for the quantiﬁcation of polymorphic forms [11]. More
accurate information can be obtained by XRPD when the tempera-
ture and/or humidity are variable.
Variable-temperature XRPD (VT-XRPD) is a technique where
XRPD experiments are carried out at different temperatures [1].
Through VT-XRPD analysis, complex pharmaceutical solid-state
reactions, including crystal structure transformations, can be char-
acterized in situ [12,13]. The VT and variable-humidity (VH) sample
chambers of the XRPD instrument allow the crystal form changes
associated with the changing conditions to be followed [14].
Other important methods of detecting polymorph transitions
are calorimetric methods such as differential scanning calorimetry
(DSC) or modulated-temperature differential scanning calorimetry
(MTDSC). DSC is widely used for polymorphism studies, because
the various crystalline polymorphs frequently differ in their heats
of fusion [2]. The occurrence of multiple peaks when a form is
heated can indicate a polymorph transformation [15]. The heating
rate may  have a great inﬂuence on the kinetics and the resolution of
peaks in DSC curves [16]. At a comparatively high heating rate (e.g.
100 ◦C min−1), the kinetics of the melting transition is changed as if
there were not enough time for recrystallization of the higher melt-
ing form [17]. With fast-scan DSC, the melting of the metastable
polymorph can be distinguished from any subsequent recrystal-
lization because the later event is moved to a higher temperature
and provides separation of the events [18].
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oFig. 1. Chemical structure of the former drug candidate.
MTDSC differs from conventional DSC in that the sample is
ubjected to a more complex heating programme, incorporating
 sinusoidal temperature modulation accompanied by an under-
ying linear heating jump ramp. While the DSC method measures
he total heat ﬂow, MTDSC can distinguish reversible (heat capac-
ty component) and non-reversible (kinetic component) heat ﬂows
oo [19].
In a previous study, a former drug candidate obtained from
anoﬁ (Hungary) was examined and 8 polymorphs (Forms I, II,
II, IVa, IVb, V, VI and VII) were generated and distinguished by
ifferent analytical methods. At the early beginning of the poly-
orph screening of this former drug candidate, it was not possible
o decide if Form IVa and IVb are a mixture of two  polymorphs or
hey are pure polymorphs, but the further analytical investigations
ould prove that they are separate forms [20].
The aim of the current study was to use three different methods
f investigation (isothermal suspension equilibration testing, XRPD
nd DSC) to study the polymorph changes of the model compound
nd to rank the polymorphs generated in terms of their relative
tability.
. Experimental
.1. Materials
The model compound used was 3-[2-({[1-(2-cyclohexylethyl)-
-(2,5-dimethoxy-4-methylphenyl)-1H-1,2,4-triazol-3-yl]amino}
arbonyl)-6-methoxy-4,5-dimethyl-1H-indol-1-yl]propanoic acid
Fig. 1). The crystallization of the various polymorphic forms
as achieved with different organic solvents of analytical grade:
cetonitrile, methanol, 96% ethanol, absolute ethanol, isopropanol,
cetone, 2-butanone, toluene (Merck, Budapest, Hungary),
ichloromethane, ethyl acetate, n-butylacetate, chloroform,
,4-dioxane (Reanal, Budapest, Hungary), and tetrahydrofuran
Aldrich, Budapest, Hungary). The polymorphs generated were
tored under normal conditions.
.2. Methods
.2.1. Isothermal suspension equilibration
An automatic laboratory reactor system (Avantium Crystal 16,
msterdam, The Netherlands) was used to investigate the relative
tabilities of the different polymorphs in suspension. Crystal 16 is
 multiple reactor system working as a parallel crystallizer on a
 ml  volume scale, equipped with an online turbidity probe. The
rganic solvents for the relative stability examination were chosen
ith regard to the solubility properties of each polymorph. The dif-
erent polymorphs were stirring in suspension in 96% ethanol as a
moderately good” solvent and in silicone oil as a heat-transferring
edium. 100 mg  samples of the polymorphs were examined in 1 ml
f 96% ethanol or silicone oil for a maximum of 130 days at room
emperature, 50 or 70 ◦C (in the case of ethanol) or at 200 ◦C (in
ase of silicone oil). Samples of the suspensions were taken out
rom time to time with a glass pipette, ﬁltered and placed on a Si
ow-background smooth-surfaced sample holder, and the crystals
btained were measured by XRPD.iomedical Analysis 102 (2015) 229–235
2.2.2. VH/VT-XRPD
VH/VT-XRPD patterns were recorded with a Bruker D8 Advance
diffractometer (Bruker AXS GmbH, Karlsruhe, Germany) system
with Cu K1 radiation ( = 1.5406 A˚) in the interval 2.5–40◦/2.
The diffractometer was equipped with a hot-humidity chamber
(MRI Physikalische Geräte GmbH, Karlsruhe, Germany) controlled
by an Ansyco Sycos H-Hot (Analytische Systeme und Componenten
GmbH, Karlsruhe, Germany) and a Våntec 1 line detector (Bruker
AXS GmbH, Karlsruhe, Germany), which indicated the phase tran-
sitions of the polymorphs directly in the diffractometer chamber.
The measurement conditions: target, Cu; ﬁlter, Ni; voltage, 40 kV;
current, 40 mA;  time constant, 0.1 s; angular step, 0.007◦.
The parameters of the VH-XRPD investigations: humidity
between 20 and 80 RH% in 10 RH% increments, and repeated mea-
surement at 20 RH%. The temperature was  30 ◦C. The VT-XRPD
studies were carried out between 30 and 230 ◦C, in increments of
5 ◦C. After the series of measurements, the samples were cooled
back to 30 ◦C and measurements were repeated immediately after
cooling and one day later.
2.2.3. DSC
The DSC analysis was carried out with a Mettler Toledo STARe
thermal analysis system, version 9.30 DSC 821e (Mettler-Toledo
AG, Greifensee, Switzerland), at a linear heating rate of 1, 10
or 30 ◦C min−1, with nitrogen as carrier gas (100 ml  min−1). The
sample weight was in the range 2–5 mg  and examinations were
performed in the temperature interval 25–250 ◦C, in a sealed 40 l
aluminium crucible having two leaks in the lid. In every case, sam-
ples were held at 25 ◦C for 10 min  before measurements.
The MTDSC parameters: temperature interval, 25–250 ◦C; heat-
ing rate: 10 ◦C min−1; amplitude: 0.5 or 1 ◦C; period: 0.5 or 1 min.
3. Results and discussion
3.1. Isothermal suspension equilibration
When the ethanol suspensions were slurried at room tempera-
ture, Forms I, V, VI and VII turned into Form III, whereas Forms II, III,
IVa and IVb did not undergo any change within 130 days. At 50 ◦C,
Form I was transformed to Form III, and Form III was transformed
to Form IVb. The other forms investigated (Form II, IVa and IVb)
remained unchanged. At 70 ◦C, Form I turned into Form II, Form III
into Form IVb, and Form IVa to Form IVb, while Forms II and IVb
did not change during the investigated period.
When the polymorphs of the model compound were slurried
in silicone oil at 200 ◦C, Forms I and III turned into Form II and
Form IVa into Form IVb. The other forms were not investigated. No
interchange was  observed between Forms II and IVb.
3.2. VH-XRPD
VH-XRPD analysis on each of the 8 polymorphs clearly showed
that all of the polymorphs were stable in the range 20–80 RH% and
at 20 RH% in the repeated measurements. As an example, the results
of the investigation of Form I are presented in a two-dimensional
ﬁgure (Fig. 2), where the intensities of the reﬂections are propor-
tional to the intensity of the grey colour.
Neither new reﬂection peaks nor intensity differences were
detected during the examinations of these 8 polymorphs when the
RH in the measuring chamber was either increased or decreased.
3.3. VT-XRPDThe in situ VT-XRPD investigations yielded some interesting
results as concerns the polymorph transformation screening pro-
cess. The intensities of the diffraction peaks of Form I decreased
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ontinuously during heating. The transformation of Form I started
t about 155 ◦C and ﬁnished at about 190 ◦C (Fig. 3). After cooling
ack, the intensities of the diffraction peaks were slightly increased
s compared with those of the sample measured at 200 ◦C. The
esult of the transformation was Form II. The volume change caused
y the temperature change resulted in slight shifts in the reﬂection
eaks. A similar phenomenon was observed in the examination of
ach polymorph.
The temperature increase did not cause any phase transition
f Form II; this polymorphic form remained stable until melting
30 ◦C and after cooling back to 20 ◦C (Fig. 4). The VT-XRPD inves-
igation indicated that this form was the stable one, and this was
onﬁrmed by the DSC studies.The phase transition of Form III started at about 215 ◦C.
fter recooling, the new low-intensity reﬂection peaks measured
t 230 ◦C were increased signiﬁcantly; Form II was identiﬁed.
he shifting of the smaller-intensity reﬂection peaks at 2
Fig. 3. 2D VT-XRPD diffractogram of F
Fig. 4. 2D VT-XRPD diffractogram of Finterval 20–80 RH% and repeated at 20 RH%.
values of about 16–17 and the larger-intensity peaks at 2 val-
ues of around 25 started at 160 ◦C, which indicated the earlier
onset of this phase transition with some content of Form I
(Fig. 5).
Increase of the temperature did not cause any changes in the
Form IVa and IVb polymorphs up to 225 ◦C. Further increase of
temperature resulted in the melting of these samples, and after
cooling back to 30 ◦C the samples became amorphous. Repeated
measurements on the next day veriﬁed the persistence of the amor-
phous form. Because of the limitations of the VT-XRPD instrument,
it was  not able to achieve a sufﬁciently high temperature for the
transformation of Form IVa to Form IVb.
During the heating of Form V, the disappearance of diffraction
peaks was observed at about 145 ◦C. Thermomicroscopic stud-
ies conﬁrmed that this phenomenon was caused by the melting
process. Crystallization of the melt started at about 150 ◦C. The
diffractogram of this new form (Intermediate I) was different from
orm I in the interval 30–200 ◦C.
orm II in the interval 30–230 ◦C.
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hat of any other polymorph. During further heating of the mate-
ial, a phase-transition process started at about 190 ◦C, resulting in
 second new form (Intermediate II), and Form II ﬁnally crystallized
t about 220 ◦C. The diffraction peaks of the material cooled down
o 20 ◦C those of pure Form II (Figs. 6 and 7).
During the heating of Form VI two phase-transition processes
ere detected, at onset temperatures of about 175 ◦C and 190 ◦C.
he result of the ﬁrst process was the same as the previously
etected Intermediate I, while the second series of peaks were those
f Form II (Fig. 8).
Fig. 6. 2D VT-XRPD diffractogram of F
Fig. 7. VT-XRPD diffractograms of Form III in the interval 30–230 ◦C.
Finally, similarly to Form I, Form VII was transformed to Form
II. The onset temperature of the phase transition was about 190 ◦C.
Intermediates I and II could not be prepared in this investigation.
These two  forms are instable forms; all attempts to isolate them
resulted in the stable Form II.3.4. DSC
DSC investigations of all the polymorphic forms were per-
formed at several heating rates. The results of these studies
orm V in the interval 30–230 ◦C.
rm V at several temperatures.
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Fig. 8. 2D VT-XRPD diffractogram of Form VI in the interval 30–230 ◦C.
Fig. 9. DSC curves of Form I at different heating rates.
Fig. 10. DSC curves of Form III at different heating rates.
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Fig. 11. DSC curves of Form V at different heating rates.
Table 1
The relevant DSC data of the 8 polymorphs.
Form Tonset (◦C) ±s.d. H (J g−1) ±s.d.
I 229.9 0.7 −49.0 0.2
II  230.8 0.6 −93.6 0.5
III  212.8 0.5 −70.5 0.5
IVa  215.7 0.1 −56.7 0.7
IVb  218.9 0.3 −56.2 0.2
V  121.3 0.3 −11.0 0.6
c
i
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n
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i
1
b
i
cVI  170.0 0.1 −43.9 0.1
VII  178.7 0.4 −57.9 0.2
onﬁrmed the ﬁndings of the XRPD investigations. The DSC stud-
es carried out at different heating rates led to different results.
oth the low (1 ◦C min−1) and the high (30 ◦C min−1) heating rate
tudies provided additional information on the phase-transition
rocesses.
The polymorph phase-transition peak of Form I could not be
etected at low heating rate. However, a heating rate of 30 ◦C min−1
aused a small exothermic peak at an onset temperature of 190 ◦C,
hich indicated that Form I was transformed into the more stable
orm II. It was also observed that a higher heating rate generally
aused the peaks to shift towards higher temperatures (Fig. 9). A
imilar phenomenon was observed for Form VII.
Depending on the heating rate, DSC curves of Form II contained
ne endothermic peak at about 231–235 ◦C, which corresponded
o the melting point of the most stable Form II.
The phase-transition process of Form III to Form II was  seen in a
ower heating rate DSC curve (an endothermic peak at 213 ◦C and a
ubsequent exothermic peak at 214–215 ◦C). These processes could
ot be distinguished from each other at the highest heating rate.
he slow phase-transformation process between 160 and 215 ◦C
escribed in the XRPD investigations was not be detected in the
SC curves (Fig. 10).
In the DSC curves of Form V the endothermic peak of melt-
ng could be identiﬁed at about 132–146 ◦C. At heating rates of
◦ −1 and 10 C min , only the ﬁrst phase-transition process could
e observed, which was shifted towards higher temperatures on
ncrease of the heating rate. The two phase-transition processes
ould be seen only in the DSC curve at higher heating rate (Fig. 11).Fig. 12. Flowchart of phase-transition processes.
The phase-transition process of Form VI was detected in the
DSC curve at the heating rate of 10 ◦C min−1. The endothermic
and exothermic pair at about 178 and 186 ◦C corresponded to the
appearance of the Intermediate I form. The phase transition could
not be detected at a heating rate of 1 ◦C min−1, while the subpro-
cesses could not be separated from each other at a heating rate of
30 ◦C min−1.
The MTDSC investigations did not provide more information
on the relative stability of the polymorphs, and these results are
therefore not presented here.
The enthalpies of Forms III, IVa, VI and VII were only estimated,
due to the inability to obtain a single melting endotherm. The
enthalpy of the melting endotherm for Form II was  found to be
the highest, and that for Form V was  the lowest (Table 1). Form II
was not transformed to Form IVb or vice versa.4. Conclusions
The relative stabilities of the polymorphs of a former-drug can-
didate were investigated by an isothermal suspension equilibration
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ethod, variable-humidity and temperature X-ray powder diffrac-
ion and differential scanning calorimetry. The summarized results
f the studies are presented in a ﬂowchart (Fig. 12).
The isothermal suspension equilibration and VT-XRPD methods
ed to different phase-transformation processes for some poly-
orphic forms. The phase-transition processes were conﬁrmed by
SC studies carried out at different heating rates. The VT-XRPD
nvestigations demonstrated the formation of two  new unstable
ntermediate forms (from Forms V and VI). Forms IVa and IVb
esulted in amorphous materials. Variation of the relative humidity
ad no inﬂuence on the polymorphic transformations. It was con-
luded that Forms I, III, IVa, V, VI and VII are metastable forms, while
orm IVb has almost the same stability as that of Form II because the
ransformation of Form IVb to Form II (and vice versa) has not been
chieved to date. The enthalpy data, the isothermal suspension
quilibration investigations and the XRPD results conﬁrmed that
he thermodynamically stable polymorph is Form II. It may be noted
hat the VT-XRPD method is a very useful technique for the analysis
f phase-transition processes. The application of different heat-
ng rates during the DSC tests is recommended in order to obtain
ppropriate information about the details of phase-transformation
rocesses.
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